<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4427008</article-id><article-id pub-id-type="doi">10.1155/2015/470805</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Vitamin D and Inflammatory Bowel Disease </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ardesia</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ferlazzo</surname><given-names>Guido</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fries</surname><given-names>Walter</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Internal Medicine, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy</aff><aff id="I2"><sup>2</sup>Laboratory of Immunology and Biotherapy, Department of Human Pathology, University of Messina, Messina, Italy</aff><aff id="I3"><sup>3</sup>Clinical Unit for Chronic Bowel Disorders, IBD-UNIT, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 1, 98125 Messina, Italy</aff><author-notes><corresp id="cor1">*Walter Fries: <email>fwalter@unime.it</email></corresp><fn fn-type="other"><p><text><SENT sid="1" pm="."><plain>Academic Editor: K. Šebeková </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><year>2015</year></pub-date><pub-date pub-type="epub"><day>27</day><month>4</month><year>2015</year></pub-date><volume>2015</volume><elocation-id>470805</elocation-id><history><date date-type="received"><day>27</day><month>11</month><year>2014</year></date><date date-type="rev-recd"><day>2</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>Copyright © 2015 Marco Ardesia et al.</copyright-statement><copyright-year>2015</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Vitamin D deficiency has been recognized as an environmental risk factor for Crohn's disease since the early 80s. </plain></SENT>
<SENT sid="3" pm="."><plain>Initially, this finding was correlated with metabolic bone disease. </plain></SENT>
<SENT sid="4" pm="."><plain>Low serum 25-hydroxyvitamin D levels have been repeatedly reported in inflammatory bowel diseases together with a relationship between vitamin D status and disease activity. </plain></SENT>
<SENT sid="5" pm="."><plain>Subsequently, low serum vitamin D levels have been reported in various immune-related diseases pointing to an immunoregulatory role. </plain></SENT>
<SENT sid="6" pm="."><plain>Indeed, vitamin D and its receptor (VDR) are known to interact with different players of the immune homeostasis by controlling cell proliferation, antigen receptor signalling, and intestinal barrier function. </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, 1,25-dihydroxyvitamin D is implicated in NOD2-mediated expression of defensin-β2, the latter known to play a crucial role in the pathogenesis of Crohn's disease (IBD1 gene), and several genetic variants of the vitamin D receptor have been identified as Crohn's disease candidate susceptibility genes. </plain></SENT>
<SENT sid="8" pm="."><plain>From animal models we have learned that deletion of the VDR gene was associated with a more severe disease. </plain></SENT>
<SENT sid="9" pm="."><plain>There is a growing body of evidence concerning the therapeutic role of vitamin D/synthetic vitamin D receptor agonists in clinical and experimental models of inflammatory bowel disease far beyond the role of calcium homeostasis and bone metabolism. </plain></SENT>
</text></SecTag></p></abstract></article-meta></front><body><SecTag type="INTRO"><sec id="sec1"><title><text><SENT sid="10" pm="."><plain>1. </plain></SENT>
<SENT sid="11" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="12" pm="."><plain>Vitamin D is a fat-soluble vitamin whose active form, calcitriol or 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), regulates bone, calcium, and phosphorus metabolism [1]. </plain></SENT>
<SENT sid="13" pm="."><plain>However, vitamin D also influences immune system function, and deficiency has been recognized as an environmental risk factor for autoimmune diseases like Crohn's disease (CD) [2]. </plain></SENT>
</text></p><p><text><SENT sid="14" pm="."><plain>In humans, vitamin D may be obtained from two sources: diet (as fat-soluble vitamin) and by ultraviolet- (UV-) mediated synthesis in the epidermal layer of the skin where UV-rays promote photolytic cleavage of 7-dihydrocholesterol (7-HDC) into vitamin D3 [3]. </plain></SENT>
<SENT sid="15" pm="."><plain>The latter is the most important source of this metabolite and, at this point, vitamin D can be considered as a hormone [4]. </plain></SENT>
<SENT sid="16" pm="."><plain>After production, vitamin D is activated by a two-step hydroxylation, first in the carbon 5-position by 25-hydroxylase in the liver then by 1α-hydroxylase in the kidney: this active metabolite exerts its functions by interacting with the vitamin D receptor (VDR), a receptor that belongs to the superfamily of nuclear hormone receptors [1]. </plain></SENT>
<SENT sid="17" pm="."><plain>Binding to VDR leads to the transcription of several vitamin D-response genes, located on single loci [5]. </plain></SENT>
<SENT sid="18" pm="."><plain>Various tissues and, especially, immune-related cells express VDRs and are able to produce 1,25(OH)2D3. </plain></SENT>
<SENT sid="19" pm="."><plain>This implies that the vitamin exerts its action beyond its classic hormonal-endocrine function tending towards an autocrine role [6]. </plain></SENT>
</text></p></sec></SecTag><sec id="sec2"><title><text><SENT sid="20" pm="."><plain>2. </plain></SENT>
<SENT sid="21" pm="."><plain>Vitamin D and Its Role in Immune Regulation </plain></SENT>
</text></title><p><text><SENT sid="22" pm="."><plain>Vitamin D affects the immune system acting at various levels, such as antibacterial response, antigen presentation, and regulation of adaptive and innate immunity. </plain></SENT>
<SENT sid="23" pm="."><plain>Genome-wide analysis has revealed that a large number of genes are influenced by vitamin D levels [7]. </plain></SENT>
<SENT sid="24" pm="."><plain>VDRs have been discovered in almost all immune cells as activated or naïve CD4+ and CD8+ T cells, B cells, neutrophils, and antigen-presenting cells (APCs) such as dendritic cells and macrophages. </plain></SENT>
<SENT sid="25" pm="."><plain>In particular, vitamin D3 enhances the chemotactic and phagocytic responses of macrophages and production of antimicrobial proteins, such as cathelicidin, inhibits the surface expression of the MHC-II-complex antigen and costimulatory molecules and downregulates the production of many proinflammatory cytokines, such as interleukin- (IL-) 1, IL-6, IL-8, and TNF-α [4, 8]. </plain></SENT>
<SENT sid="26" pm="."><plain>An experimental study demonstrated that transferring CD8+ T cells isolated from the spleen of wild type (WT) and IL-10 KO mice into immunodeficient Rag KO recipients, that is, mice with no mature B or T cells, did not induce colitis, whereas transferring CD8+ T cells from VDR KO mice led to colonic inflammation, and transferring CD8+ T cells from IL-10/VDR KO mice led to fulminant colitis. </plain></SENT>
<SENT sid="27" pm="."><plain>These data indicate that expression of VDR is required to prevent replication of quiescent CD8+ T cells and that the lack of VDR induced the formation of more aggressive T cells [9]. </plain></SENT>
<SENT sid="28" pm="."><plain>Another study evaluated the difference of protein expression in the small intestinal mucosa between WT mice and VDR KO mice identifying a higher expression of proteins involved in cell adhesion, proliferation, and migration and stress response in VDR KO mice. </plain></SENT>
<SENT sid="29" pm="."><plain>The authors conclude that vitamin D and VDR play a direct, or indirect role, in balancing these functions [10]. </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>Vitamin D/VDR status regulates development, function, and balance of T-lymphocytes dampening T-helper- (Th-) 1 cell function and cytokine patterns (IL-2 and interferon-γ (IFN-γ)) by enhancing the Th-2 cell response (IL-4, IL-5, and IL-10) [11]; moreover 1,25(OH)2D3 promotes a regulatory outcome through the inhibition of Th-17 cells and their related cytokines, and the induction of regulatory T cells (Treg) that are protective against autoimmunity, stimulating the expression of the cytotoxic T-associated protein 4 (CTLA-4) and forkhead box P3 (Foxp-3), together with the induction of IL-10 [12, 13]. </plain></SENT>
<SENT sid="31" pm="."><plain>In addition, 1,25(OH)2D3 appears to have a chemopreventive role through an antiproliferative action, for example, through VDR-mediated inhibition of the Wnt/beta-catenin pathway [8, 14, 15], inhibiting growth without inducing apoptosis and inducing differentiation in colon cancer cell lines [16, 17]. </plain></SENT>
</text></p><p><text><SENT sid="32" pm="."><plain>The molecular and genetic link between CD and the vitamin D/immune system axis may be in part explained by the NOD2 gene (Figure 1). </plain></SENT>
<SENT sid="33" pm="."><plain>The precise etiology of the inflammatory bowel disease CD is unknown. </plain></SENT>
<SENT sid="34" pm="."><plain>Like many chronic diseases, there are environmental factors that act on a polygenic background. </plain></SENT>
<SENT sid="35" pm="."><plain>Variants of the NOD2/CARD15 gene are associated with the development and phenotypic patterns of CD. </plain></SENT>
<SENT sid="36" pm="."><plain>This gene encodes for a protein of the family of intracellular pattern recognition receptors for bacterial components that play an important role in the innate immune system [18, 19]. </plain></SENT>
<SENT sid="37" pm="."><plain>Transcription of the NOD2 gene is stimulated by 1,25(OH)2D3/VDR and signaling through NOD2 induces expression of DEFB2/HBD2 which stands for the antimicrobial peptide beta-defensin 2, and of CAMP which codifies for cathelicidin [20]. </plain></SENT>
<SENT sid="38" pm="."><plain>In a study on a VDR KO model, a downregulation of the ATG16L1 gene, together with a reduced expression of lysozyme by Paneth cells was reported [21]. </plain></SENT>
<SENT sid="39" pm="."><plain>These mice had an increased susceptibility to dextran sulfate sodium (DSS) colitis, whereas in human colon samples of low VDR expression correlate with ATG16L1 and a reduction of Bacteroides species. </plain></SENT>
<SENT sid="40" pm="."><plain>This finding implies that alterations of the vitamin D status might interfere with autophagy and alter the antimicrobial barrier of the intestinal mucosa and, consequently, the control of the microbiota [22]. </plain></SENT>
</text></p></sec><sec id="sec3"><title><text><SENT sid="41" pm="."><plain>3. </plain></SENT>
<SENT sid="42" pm="."><plain>VDR Polymorphisms in IBD </plain></SENT>
</text></title><p><text><SENT sid="43" pm="."><plain>From the above, it appears that variants of VDR interfere with the immune system and, thus, may contribute to susceptibility to inflammatory bowel disease (IBD) [23, 24]. </plain></SENT>
<SENT sid="44" pm="."><plain>In fact, VDR polymorphisms have been identified in various diseases, such as cancer [25] or cancer risk [26], asthma [27], and kidney diseases [28]. </plain></SENT>
<SENT sid="45" pm="."><plain>The best-studied polymorphisms include BsmI (rs1544410), FokI (rs2228570), TaqI (rs731236), and ApaI (rs7975232). </plain></SENT>
<SENT sid="46" pm="."><plain>However, the results of these still few studies in IBD patients are contradictory (Table 1): for example, no statistical significance compared to controls was found in two studies on IBD patients for BsmI, FokI, TaqI, and ApaI [29, 30] with a borderline significance for heterozygous carriage of the FokI allele [29]. </plain></SENT>
<SENT sid="47" pm="."><plain>In three Chinese studies on ulcerative colitis (UC) patients [31, 32] and on CD patients, no difference [32] or an association of the Bb genotype of the BsmI variant with UC [31] was reported; whereas no association was found for ApaI, TaqI, and BsmI with CD [33]. </plain></SENT>
</text></p><p><text><SENT sid="48" pm="."><plain>In another study on European Caucasian patients, a significantly higher frequency of the TaqI polymorphism (genotype “tt”) was reported in CD compared to UC or HC [23]. </plain></SENT>
<SENT sid="49" pm="."><plain>This finding was replicated in German IBD patients where the “tt” genotype was significantly more frequent in fistulizing and stenosing CD [24]. </plain></SENT>
<SENT sid="50" pm="."><plain>Subsequently, always in Caucasians, the finding of a lack of association of ApaI but a more frequent presence of TaqI in male IBD patients was reported [34] and confirmed 3 years later [35]. </plain></SENT>
</text></p><p><text><SENT sid="51" pm="."><plain>Concerning BsmI polymorphisms, the BB genotype was more frequent in Ashkenazi UC patients compared to Ashkenazi controls [36]. </plain></SENT>
<SENT sid="52" pm="."><plain>Finally, in a mixed IBD population investigating all 4 VDR variants, only the Fok I variant (“ff” genotype) was significantly more frequent in IBD patients [37]. </plain></SENT>
</text></p><p><text><SENT sid="53" pm="."><plain>Two recent meta-analyses including the same 9 studies with slightly different patient numbers (Table 1) yielded different results [38, 39]; Xue et al. [38] found that the “ff” genotype of FokI was associated with a significant risk for UC in Asians, whereas the “tt” genotype of TaqI was associated with an increased risk for CD in Europeans, but with an increased risk for both diseases, CD and UC, in Asian males. </plain></SENT>
<SENT sid="54" pm="."><plain>Carriage of the “a” allele (ApaI) resulted protective from CD. </plain></SENT>
<SENT sid="55" pm="."><plain>In contrast, Wang et al. [39] concluded that there was no association between ApaI, BsmI, and FokI and IBD, whereas subgroup analysis evidenced an increased risk for CD for ApaI and limited to East Asians, for BsmI. </plain></SENT>
<SENT sid="56" pm="."><plain>Conversely, TaqI variants reduced the risk for UC in Caucasians. </plain></SENT>
</text></p><p><text><SENT sid="57" pm="."><plain>One study examined the influence of VDR polymorphisms on serum vitamin D levels [40] (not included in Table 1) showing a significant association of variants of the TaqI and the signal peptide, CUB domain, and EGF-like 3 (SCUBE3, rs732594) genes, the latter encodes for a protein involved in the VDR pathway, in CD patients, whereas ApaI and SCUBE3 and two variants of PHD finger protein-11 (PHF-11) gene, namely, rs2980 and rs2981, showed a significant association with serum vitamin D levels in CD patients. </plain></SENT>
<SENT sid="58" pm="."><plain>PHF-11 variants have been shown to be involved with vitamin D levels in other pathologies, such as asthma [41]. </plain></SENT>
</text></p><p><text><SENT sid="59" pm="."><plain>Besides investigations on VDR variants, 2 SNPs of the vitamin D-binding protein (DBP), that is, the 416 variant Glu (rs7041) and the 420 variant Lys (rs4588), were analysed. </plain></SENT>
<SENT sid="60" pm="."><plain>A significantly reduced frequency of the 420 variant Lys was found in IBD patients compared to controls [42]. </plain></SENT>
</text></p><p><text><SENT sid="61" pm="."><plain>In conclusion, the influence of VDR variants on IBD risk is still poorly defined. </plain></SENT>
<SENT sid="62" pm="."><plain>Interesting approaches are represented by investigations on the association between polymorphisms and vitamin D levels and those examining proteins involved in vitamin D-related pathways, but all need further studies and confirmation. </plain></SENT>
</text></p></sec><sec id="sec4"><title><text><SENT sid="63" pm="."><plain>4. </plain></SENT>
<SENT sid="64" pm="."><plain>Vitamin D Status and Related Risk Factors in IBD </plain></SENT>
</text></title><p><text><SENT sid="65" pm="."><plain>Starting in the late seventies, investigations on the vitamin D status of IBD patients have been carried out with different methodological approaches and results. </plain></SENT>
<SENT sid="66" pm="."><plain>By comparing IBD patients (CD alone or mixed populations) versus healthy controls (HC), no differences were found for circulating 25(OH)D3 concentrations in 6 studies on adult IBD populations [43–48] and in 1 study on a pediatric cohort [49], whereas lower plasma levels were reported in undernourished CD patients [50], in CD patients after intestinal resections [51], in 2 studies on adult, and in 1 study on pediatric CD patients [52–54] and in 3 mixed IBD populations [55–57]. </plain></SENT>
</text></p><p><text><SENT sid="67" pm="."><plain>Comparing 25(OH)D3 levels between CD and UC patients, no differences were found in 8 studies on adult or pediatric patients in basal conditions [47, 54, 55, 57–61] and in 1 pediatric study on partially vitamin D supplemented patients [62]. </plain></SENT>
<SENT sid="68" pm="."><plain>Lower levels in CD compared with UC were found in 5 studies [46, 63–66]. </plain></SENT>
</text></p><p><text><SENT sid="69" pm="."><plain>Finally, investigations concerning the active form of vitamin D, 1,25(OH)2D3, reported normal levels after bowel resections in CD [67] but no differences between well- and undernourished CD patients compared to HC or in well-nourished UC patients [50]. </plain></SENT>
<SENT sid="70" pm="."><plain>Similar findings were reported in a pediatric study including CD, UC and HC [61]. </plain></SENT>
<SENT sid="71" pm="."><plain>Lower 1,25(OH)2D3 concentrations compared to controls were found in 2 studies including CD and UC patients [45, 68]. </plain></SENT>
<SENT sid="72" pm="."><plain>Conversely, elevated levels of 1,25(OH)2D3 were reported after ileal resections in CD [51]. </plain></SENT>
<SENT sid="73" pm="."><plain>In this latter study, a positive correlation with 25(OH)D3 levels and PTH was reported. </plain></SENT>
</text></p><p><text><SENT sid="74" pm="."><plain>Changing methodology and introducing vitamin D reference values as parameter, the importance of vitamin D in IBD has become more convincing. </plain></SENT>
<SENT sid="75" pm="."><plain>Defining vitamin sufficiency as serum values above 30 ng/mL, vitamin D insufficiency as values between 10/20 and 30 ng/mL, and vitamin deficiency as concentrations below 10 to 15 ng/mL, data from 27 studies from all over the world were available [44, 46, 52, 53, 56–58, 60, 61, 63, 64, 69–77], 6 of them on cohorts over 100 participants [59, 62, 66, 78–80], and one with more than 1,000 patients [81]. </plain></SENT>
<SENT sid="76" pm="."><plain>In synthesis, vitamin deficiency was found in 8-100% of patients with CD and in 15-60% of patients with UC, vitamin insufficiency in 12-72.3% in CD or in mixed IBD populations and in 7-64% of UC patients. </plain></SENT>
<SENT sid="77" pm="."><plain>Five papers [53, 61, 74, 76, 82] differentiated vitamin D levels according to seasonal variations in CD patients reporting vitamin deficiency in 50–76% in winter and in 10–19% in summer months; vitamin insufficiency, where reported [76, 82], was indicated in 73–100% in winter and 55–59% in summer months. </plain></SENT>
</text></p><p><text><SENT sid="78" pm="."><plain>Studies evaluating vitamin D levels in IBD patients were all conducted after disease onset and established diagnosis, but it is not clear if vitamin D deficiency is the cause or a consequence. </plain></SENT>
<SENT sid="79" pm="."><plain>Pathogenesis of vitamin D hypovitaminosis in patients with IBD may depend on various mechanisms such as decreased exposure to sunlight or oral vitamin D intake, ileal resections leading to malabsorption or a disturbed enterohepatic circulation, and/or increased losses through the gastrointestinal system by protein-losing enteropathy [59]. </plain></SENT>
</text></p><p><text><SENT sid="80" pm="."><plain>To identify the reasons for the differences of the vitamin D status, the ability to absorb vitamin D2 was evaluated in a study by Farraye et al. [77] comparing CD patients and HC. </plain></SENT>
<SENT sid="81" pm="."><plain>In this study, 42% of CD patients were vitamin D deficient 25(OH)D3 (≤20 ng/mL), while 29% were insufficient (25(OH)D3: 21–29 ng/mL); 12 h after ingesting 50,000 IU of vitamin D2, circulating levels of this metabolite were significantly lower in CD compared with HC indicating a significant 30% reduction of the ability to absorb vitamin D2. </plain></SENT>
<SENT sid="82" pm="."><plain>In another study, on 31 CD patients and 15 HC, the capacity of absorbing orally administered vitamin D (5 μg of 25(OH)D3/kg body weight) was evaluated; 10% of CD patients showed decreased absorption of 25(OH)D3 after 4 and 8 hours [71]. </plain></SENT>
<SENT sid="83" pm="."><plain>Finally, a wide variability of absorption of vitamin D2 was reported in vitamin deficient and insufficient CD patients, but vitamin D2 absorption was significantly reduced compared with HC [77]. </plain></SENT>
</text></p><p><text><SENT sid="84" pm="."><plain>Several studies evaluated factors influencing vitamin D status hypothesizing reduced sun exposure as cause for hypovitaminosis, since a geographical north-south gradient was noted also for other autoimmune T helper- (Th-) 1-mediated diseases, like multiple sclerosis. </plain></SENT>
<SENT sid="85" pm="."><plain>The link between this gradient and the pathophysiological mechanisms that involve vitamin D status depends not only on dietary intake but also from UV exposure [83]. </plain></SENT>
<SENT sid="86" pm="."><plain>Indeed, a negative association between sun exposure and lower levels of 25(OH)D in CD was reported in Indian patients [52] and, most recently, also in Dutch CD [84] where reduced exposure to sunlight (defined as no sunny holidays, no solarium use, and more sun protection) was associated with low 25(OH)D serum levels. </plain></SENT>
</text></p><p><text><SENT sid="87" pm="."><plain>The relationship between sun exposure and the risk of developing CD or UC has been investigated by Nerich et al. [85]. </plain></SENT>
<SENT sid="88" pm="."><plain>High residential sunlight exposure was associated with a significant decreased risk of CD, but not UC. </plain></SENT>
<SENT sid="89" pm="."><plain>Four years later, the same group published similar results, that is, an increased incidence of CD with reduced sunlight exposure, in a cohort of women living in France, whereas vitamin D intake was not associated with a risk reduction in CD or UC [86]. </plain></SENT>
</text></p><p><text><SENT sid="90" pm="."><plain>Reduced UV exposure seems therefore not only to increase risk for CD, but it also seems associated with a worse outcome of disease. </plain></SENT>
<SENT sid="91" pm="."><plain>In a recent nationwide North-American study, the influence of UV exposure on hospitalization rates, length of hospital stay, and surgeries was investigated in an impressive number of IBD patients (649,932 CD, 384,267 UC, and 288,894,297 non-IBD controls). </plain></SENT>
<SENT sid="92" pm="."><plain>Reduced UV exposure led to significantly longer hospitalizations in all groups and to more frequent intestinal surgeries and deaths in CD [87]. </plain></SENT>
<SENT sid="93" pm="."><plain>Data on 25(OH)D3 were not available in this study. </plain></SENT>
<SENT sid="94" pm="."><plain>The finding that more UV exposure is associated with a minor number of surgical procedures in CD was confirmed in a subsequent study on 481,712 CD-related hospitalizations reporting 67,751 major surgical procedures [88]. </plain></SENT>
</text></p><p><text><SENT sid="95" pm="."><plain>Finally, a prospective cohort study of 72,179 women enrolled in the Nurses' Health Study addressed the question if vitamin D hypovitaminosis may, per se, represent a risk factor for the development of IBD. </plain></SENT>
<SENT sid="96" pm="."><plain>Incident cases of CD and UC were recorded over a follow-up period of 22 years. </plain></SENT>
<SENT sid="97" pm="."><plain>A 25(OH)D3 prediction score based on diet and lifestyle was developed and validated against effectively measured levels of 25(OH)D3. </plain></SENT>
<SENT sid="98" pm="."><plain>The authors showed that higher predicted plasma levels of 25(OH)D3 were associated with a significant risk reduction for CD but not for UC, suggesting that vitamin D status may contribute to the pathogenesis of CD [89]. </plain></SENT>
</text></p><p><text><SENT sid="99" pm="."><plain>After a series of contradictory and mostly negative studies on vitamin D levels in IBD patients compared with HC, more conclusive data have been produced introducing reference values. </plain></SENT>
<SENT sid="100" pm="."><plain>However, most of these studies have been aimed to investigate bone and calcium metabolism. </plain></SENT>
<SENT sid="101" pm="."><plain>Recent large cohort studies investigating UV exposure or vitamin D status estimating the risk to develop IBD have pushed forward our understanding on the potential role of vitamin D in the context of IBD. </plain></SENT>
</text></p></sec><sec id="sec5"><title><text><SENT sid="102" pm="."><plain>5. </plain></SENT>
<SENT sid="103" pm="."><plain>Vitamin D Status and Clinical Outcome in IBD Patients </plain></SENT>
</text></title><p><text><SENT sid="104" pm="."><plain>Several studies concerning the relationship between vitamin D status and clinical outcome in IBD patients have been published (Table 2). </plain></SENT>
<SENT sid="105" pm="."><plain>Almost 30 years ago, 25(OH)D3 levels in active CD were found to be lower than in quiescent CD [50]. </plain></SENT>
<SENT sid="106" pm="."><plain>Twenty years later, another study showed that low serum 25(OH)D3 levels were predicted by disease duration and activity scores in both, CD and UC [46]. </plain></SENT>
<SENT sid="107" pm="."><plain>This inverse association between disease activity and serum 25(OH)D3 levels was confirmed in a small prospective study in CD [52] and in a retrospective study on a much larger, mixed IBD population [59]. </plain></SENT>
<SENT sid="108" pm="."><plain>In this latter study, low serum 25(OH)D3 levels were associated with higher clinical activity scores in CD and in UC, but not with the risk for medical or surgical hospitalizations. </plain></SENT>
<SENT sid="109" pm="."><plain>Moreover, regression analysis found that low vitamin D levels were independently associated with quality of life (QoL) in CD patients but not in UC patients. </plain></SENT>
<SENT sid="110" pm="."><plain>A reduced QoL was reproduced by another study where vitamin insufficient patients had significantly lower QoL scores than those who were sufficient [82]. </plain></SENT>
<SENT sid="111" pm="."><plain>Finally, in a mixed IBD population, an inverse correlation between serum 25(OH)D3 concentrations and fecal calprotectin, a marker for gut inflammation, was found whereas serum CRP as a marker of systemic inflammation did not correlate with 25(OH)D3 levels [90]. </plain></SENT>
</text></p><p><text><SENT sid="112" pm="."><plain>Conversely, other studies on CD and UC patients failed to show a correlation between serum 25(OH)D3 levels and disease activity [60]. </plain></SENT>
<SENT sid="113" pm="."><plain>The same findings, that is, no association between 25(OH)D3 concentrations and disease activity, were published on a pediatric IBD population [54]. </plain></SENT>
</text></p><p><text><SENT sid="114" pm="."><plain>Going beyond disease activity, in a prospective study on the largest multicenter cohort involving 3,217 patients, low plasma 25(OH)D3 levels (&lt;20 ng/mL) were associated with an increased risk of hospitalizations and surgery for CD as well as for UC patients [81]. </plain></SENT>
<SENT sid="115" pm="."><plain>In a subset of CD patients, but not UC patients, who normalized vitamin D status, a reduction of CRP levels and the need for hospitalizations was observed. </plain></SENT>
</text></p><p><text><SENT sid="116" pm="."><plain>The likelihood for developing Clostridium difficile (Cl) colitis related to vitamin D status was investigated retrospectively. </plain></SENT>
<SENT sid="117" pm="."><plain>There was an increased risk for developing Cl colitis in patients with low plasma 25(OH)D3 levels (&lt;20 ng/mL), and an increase by 1 ng/mL of 25(OH)D3 was accompanied by a 4% risk reduction of developing Cl colitis. </plain></SENT>
<SENT sid="118" pm="."><plain>Lastly, death from Cl colitis occurred in those with lower 25(OH)D3 levels compared with survivors [91]. </plain></SENT>
<SENT sid="119" pm="."><plain>A recent study investigated the relationship between 25(OH)D3 concentrations and duration of anti-TNF therapy in IBD patients. </plain></SENT>
<SENT sid="120" pm="."><plain>Interestingly, low vitamin D levels were associated with loss of response during maintenance therapy in CD patients [92], whereas serum 25(OH)D3 levels increased with anti-TNF therapy [93]. </plain></SENT>
</text></p><p><text><SENT sid="121" pm="."><plain>The only study that investigated plasma 1,25(OH)2D3 levels found no association between 1,25(OH)2D3 levels and CDAI or CAI in Japanese patients [68]. </plain></SENT>
</text></p><p><text><SENT sid="122" pm="."><plain>From the above, it appears that low vitamin D is inversely correlated to disease activity documented by clinical scores and surrogate markers of inflammation such as CRP and fecal calprotectin; moreover, low levels were also associated with clinical outcomes, that is, surgery, response to anti-TNF therapy, Cl superinfection, and, finally, death. </plain></SENT>
<SENT sid="123" pm="."><plain>Inflammation per se has been shown to upregulate conversion from 25(OH)D3 to 1,25(OH)2D3 which may lead to a reduction of available 25(OH)D3. </plain></SENT>
<SENT sid="124" pm="."><plain>In this discussion, an observation of two recent papers may be relevant, coming from orthopaedic surgery, showing an acute reduction of 25(OH)D3 levels following a systemic inflammatory response induced by surgery, considering serum 25(OH)D3 as a negative acute phase reactant [94, 95]. </plain></SENT>
</text></p></sec><sec id="sec6"><title><text><SENT sid="125" pm="."><plain>6. </plain></SENT>
<SENT sid="126" pm="."><plain>Therapeutic Studies In Vitro and in Experimental Animals </plain></SENT>
</text></title><p><text><SENT sid="127" pm="."><plain>As a result of this evidence, vitamin D should be proposed as a therapy for IBD. </plain></SENT>
<SENT sid="128" pm="."><plain>Several experimental studies, both on animals and IBD patients, have been carried out (Table 3). </plain></SENT>
<SENT sid="129" pm="."><plain>Starting with the former, in a model of spontaneous colitis, interleukin- (IL-) 10 knock-out (KO) mice on a vitamin D deficient diet showed growth retardation and weight loss, together with a high mortality rate (58% at week 9) compared to mice on a vitamin D sufficient diet; 1,25(OH)2D3 (0.005 μg/day) supplementation starting from week 2 reduced weight loss and ameliorated histology scores, but vitamin D supplementation after symptom onset at week 7 (1,25(OH)2D3, 0.2 μg/day) did not induce significant differences compared with untreated animals, except for bowel weight indicating a reduction of inflammation in supplemented animals [96]. </plain></SENT>
<SENT sid="130" pm="."><plain>In another study, the efficacy of a low calcemic vitamin D analogue (22-ene-25-oxa-vitamin D (ZK156979)) was investigated in 2,4,6-trinitrobenzene sulfonic acid (TNBS) colitis [97]. </plain></SENT>
<SENT sid="131" pm="."><plain>Treatment was performed with 1,25(OH)2D3 (0.2 μg/kg) versus ZK156979 (0.1–2.0 μg/kg), both administered intraperitoneally (i.p.) before or after colitis induction. </plain></SENT>
<SENT sid="132" pm="."><plain>Assessment of inflammation and colitis severity was established by scoring colitis, macroscopic and histological analysis, and measurement of myeloperoxidase activity (MPO) and cytokine levels. </plain></SENT>
<SENT sid="133" pm="."><plain>The authors found that ZK156978 reduced the severity of TNBS-induced colitis with a potency comparable with that of 1,25(OH)2D3, downregulating MPO activity, tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) tissue levels, and T-box transcription factor (T-bet) expression, together with an increase of interleukin IL-10 and IL-4 tissue concentrations, without calcemic effects. </plain></SENT>
</text></p><p><text><SENT sid="134" pm="."><plain>Laverny et al. [98] studied the effect of an intrarectally administered vitamin D receptor agonist (1α,25(OH)2-16-ene-20-cyclopropyl-vitamin D3; BXL-62) in C57Bl/6 mice with dextran-sodium sulfate- (DSS-) induced (3%) colitis. </plain></SENT>
<SENT sid="135" pm="."><plain>BXL-62 treatment (1 μg/kg) compared to 1,25(OH)2D3 (0.3 μg/kg) was superior in preventing weight loss and visible fecal blood, together with better stool consistency and histology scores without inducing hypercalcemia. </plain></SENT>
<SENT sid="136" pm="."><plain>Another synthetic vitamin D agonist, 1α,25(OH)2-19-nor-14,20-bisepi-23-yne-vitamin D3 (TX527), has been shown to attenuate inflammation in the DSS model of colitis by downregulating IL-1, IL-6, IFN-γ, and TNF-α as well as the gastrointestinal glutathione peroxidase 2 [99]. </plain></SENT>
</text></p><p><text><SENT sid="137" pm="."><plain>There are three very interesting studies which associate vitamin D or its receptor with intestinal microbiota. </plain></SENT>
<SENT sid="138" pm="."><plain>First, in Cyp27b1-KO mice, that is, mice unable to produce 1,25(OH)2D3, an increased susceptibility to DSS colitis was observed [100]. </plain></SENT>
<SENT sid="139" pm="."><plain>Oral vitamin supplementation reduced weight loss, whereas treatment with antibiotics greatly attenuated colitis. </plain></SENT>
<SENT sid="140" pm="."><plain>In these mice, a reduced expression of E-cadherin on epithelial and immune cells was observed pointing towards a more “leaky” gut. </plain></SENT>
<SENT sid="141" pm="."><plain>Moreover, a reduced number of tolerogenic dendritic cells were observed in the gut of Cyp27b1-KO mice. </plain></SENT>
<SENT sid="142" pm="."><plain>In these mice, as well as in VDR-KO mice, dysbiosis of the microbiota was observed with an increase of the Helicobacteraceae family and a reduction of the Firmicutes and Deferribacteres phyla. </plain></SENT>
<SENT sid="143" pm="."><plain>The authors concluded that vitamin D (production or its receptor) is involved in the regulation of the gut microbiota. </plain></SENT>
<SENT sid="144" pm="."><plain>Second, DSS-induced colitis was reduced together with a lower penetration of adherent-invasive E. coli (AIEC) in mice on a vitamin-sufficient diet compared to those fed a vitamin D deficient diet. </plain></SENT>
<SENT sid="145" pm="."><plain>Moreover, vitamin D hypovitaminosis and DSS colitis led to an increase of Bacteroidetes. </plain></SENT>
<SENT sid="146" pm="."><plain>In the same paper in Caco cells incubated with or without vitamin D and then challenged with AIEC, vitamin D maintained transepithelial resistance and prevented tight junctional protein redistribution [101]. </plain></SENT>
<SENT sid="147" pm="."><plain>The third paper, that reported changes of the microbiota related to interference in the vitamin D system, assessed susceptibility to DSS colitis in conditional VDR KO mice (deletion restricted to the intestinal epithelial cells), along with Paneth cell quantity and quality by means of quantification of lysozyme and ATG16L1 protein expression. </plain></SENT>
<SENT sid="148" pm="."><plain>The latter is a protein involved in autophagy, and its genetic variants are well known as risk factors for CD. </plain></SENT>
<SENT sid="149" pm="."><plain>In this model, an increase of E. coli and Bacteroides, together with a decrease of butyrate producing bacteria was reported. </plain></SENT>
<SENT sid="150" pm="."><plain>Supplementing butyrate to IL-10 KO mice reverses reduced VDR and ATG16L1 expression. </plain></SENT>
<SENT sid="151" pm="."><plain>Similar results, that is, an increased expression of VDR and ATG16L1, were obtained incubating several cell lines with butyrate [21]. </plain></SENT>
</text></p><p><text><SENT sid="152" pm="."><plain>Finally, a reduction of intestinal fibrosis, assessed by production of extracellular matrix and total collagen, was seen in mice with TNBS colitis on a vitamin supplemented diet compared to mice fed a vitamin D deficient diet [102]. </plain></SENT>
<SENT sid="153" pm="."><plain>Moreover, in isolated subepithelial myofibroblasts from the colon, a vitamin D sufficient diet reduced concentrations of TGF-β1, Smad 3, p-Smad 3, and collagen I. </plain></SENT>
<SENT sid="154" pm="."><plain>It was concluded that preventive vitamin D administration reduces fibrosis inhibiting the VDR-mediated TGF-β1/Smad 3 pathway. </plain></SENT>
</text></p><p><text><SENT sid="155" pm="."><plain>In the above studies, in various types of spontaneous or chemically induced colitis and in several cell lines, vitamin D and synthetic agonists have been shown to reduce colitis severity and intestinal fibrosis. </plain></SENT>
<SENT sid="156" pm="."><plain>Vitamin D hypovitaminosis or knocking down Cyp27b1 or VDR had the opposite results. </plain></SENT>
<SENT sid="157" pm="."><plain>Interestingly, these latter conditions were all associated with changes of the intestinal microbiota. </plain></SENT>
</text></p></sec><sec id="sec7"><title><text><SENT sid="158" pm="."><plain>7. </plain></SENT>
<SENT sid="159" pm="."><plain>Therapeutic Studies in Human Ex Vivo Preparations </plain></SENT>
</text></title><p><text><SENT sid="160" pm="."><plain>In an ex vivo study on PBMC obtained from IBD patients and incubated in the presence of 1,25(OH)2D3, a reduction of interferon- (IFN-) γ and an increase of IL-10 production were observed in PBMC from UC patients whereas in CD the production of TNF-α were reduced [103]. </plain></SENT>
<SENT sid="161" pm="."><plain>The effect of orally administered vitamin D3 on monocyte-depleted PBMC from vitamin D3-treated (1200 IU vitamin D daily over 1 year) versus placebo-treated patients was investigated [104]. </plain></SENT>
<SENT sid="162" pm="."><plain>CD4+ T-cell proliferation and T-cell cytokine production were assessed. </plain></SENT>
<SENT sid="163" pm="."><plain>IL-6 production in vitamin D3-treated patients increased, whereas TNF-α, IFN-γ, and IL-4 did not. </plain></SENT>
<SENT sid="164" pm="."><plain>No change was observed for IL-10 and the percentage of the CD4+, CD25+, and Foxp3+ regulatory T cells compared to placebo. </plain></SENT>
<SENT sid="165" pm="."><plain>The amount of proliferating CD4+ T cells was significantly increased (from 41% to 56%) in the vitamin-D-treated group. </plain></SENT>
</text></p><p><text><SENT sid="166" pm="."><plain>Another ex vivo study employed the vitamin D analogue (19-nor-14,20-bisepi-23-yne-1,25(OH)2D3; TX 527). </plain></SENT>
<SENT sid="167" pm="."><plain>This analogue significantly inhibited PBMC proliferation and TNF-α release in CD and HC [105]. </plain></SENT>
<SENT sid="168" pm="."><plain>The increase of VDR protein levels after incubation with TX 527 was higher in CD compared with HC. </plain></SENT>
<SENT sid="169" pm="."><plain>Moreover, in PBMC of both, HC and CD, stimulated with TNF-α, a decrease in nuclear NF-κB protein levels together with an increase in cytoplasmic IKB-α levels were observed pointing to an inhibition of TNF-α induced effects on PBMC exerted by the vitamin D analogue. </plain></SENT>
</text></p><p><text><SENT sid="170" pm="."><plain>The effect of the vitamin receptor agonist BXL-62 on PBMC from CD and UC patients and lamina propria mononuclear cells (LPMC) obtained from biopsies of two CD (ileum) and two UC (colon) patients was investigated [98]. </plain></SENT>
<SENT sid="171" pm="."><plain>After incubation, in LPS-stimulated PBMC and in activated LPMC from IBD patients, BXL-62 significantly inhibited, with a significantly higher potency compared with 1,25(OH)2D3, TNF-α, IL-6, and IL-12/23p40 transcription and cytokine concentrations measured in culture supernatants without differences between CD and UC. </plain></SENT>
</text></p><p><text><SENT sid="172" pm="."><plain>In PBMC of CD patients, expression of the CYP27B1 gene, that is, the gene that encodes the enzyme that converts 25(OH)D3 to 1,25(OH)2D3, and that of the VDR gene was investigated, showing a higher expression in active compared to inactive disease [93]. </plain></SENT>
<SENT sid="173" pm="."><plain>Moreover, CD4+ T cells incubated in the presence of vitamin D showed a threefold increase of CD25+ cells. </plain></SENT>
</text></p><p><text><SENT sid="174" pm="."><plain>Finally, the effect of oral vitamin D supplementation on the maturation and cytokine production of monocyte-derived dendritic cells of CD patients was studied [106]. </plain></SENT>
<SENT sid="175" pm="."><plain>Compared to placebo-treated CD patients, vitamin D supplementation led to reduced CD80 expression in LPS-stimulated dendritic cells together with reduced production of IL-10, IL-1β, and IL-6. </plain></SENT>
</text></p></sec><sec id="sec8"><title><text><SENT sid="176" pm="."><plain>8. </plain></SENT>
<SENT sid="177" pm="."><plain>Therapeutic Studies in Human IBD </plain></SENT>
</text></title><p><text><SENT sid="178" pm="."><plain>There are only few studies with vitamin D addressing the clinical course of IBD (Table 3). </plain></SENT>
<SENT sid="179" pm="."><plain>In one of these studies, the effect of supplementation of the active form of vitamin D 1,25(OH)2D3 (aVD, 1000 IU 1.25(OH)2D3 daily) versus the plain vitamin D 25(OH)D (pVD; 2 × 0.25 μg alphacalcidiol daily) was investigated in CD patients in clinical remission (CDAI &lt; 150) [107]. </plain></SENT>
<SENT sid="180" pm="."><plain>Both groups received oral calcium supplementation (1000 mg/day). </plain></SENT>
<SENT sid="181" pm="."><plain>At 6 weeks, the mean CDAI and IBDQ scores, as well as the CRP concentrations, decreased in the aVD-treated group, but not in the pVD-treated group. </plain></SENT>
<SENT sid="182" pm="."><plain>These differences between the groups however disappeared by week 52. </plain></SENT>
<SENT sid="183" pm="."><plain>Serum calcium concentrations did not change at any time point. </plain></SENT>
<SENT sid="184" pm="."><plain>Jørgensen et al. [108] performed a randomized double-blind placebo-controlled multicenter study to assess the benefit of vitamin D3 treatment in CD. </plain></SENT>
<SENT sid="185" pm="."><plain>They included 94 CD patients in clinical (CDAI &lt; 150) and biochemical remission, randomized to receive 1200 IU of vitamin D3 + 1200 mg of calcium or 1200 mg of calcium alone. </plain></SENT>
<SENT sid="186" pm="."><plain>During 1-year follow-up, serum 25(OH)D3 levels increased significantly in vitamin D-supplemented patients, on average from 27 to 38 ng/mL, but free serum calcium did not change. </plain></SENT>
<SENT sid="187" pm="."><plain>The relapse rate (defined as increase of CDAI &gt;70 over baseline and CDAI ≥150) was not significantly lowered. </plain></SENT>
<SENT sid="188" pm="."><plain>Adjustment for the use of azathioprine and smoking resulted in minor changes of the risk estimate. </plain></SENT>
<SENT sid="189" pm="."><plain>However, the authors concluded that vitamin D might be effective in CD but claimed the need for larger studies. </plain></SENT>
</text></p><p><text><SENT sid="190" pm="."><plain>In an uncontrolled study, 18 active CD patients were initially treated with 1000 IU vitamin D daily over 2 weeks. </plain></SENT>
<SENT sid="191" pm="."><plain>Thereafter, the dose was escalated (to a maximum of 5000 IU) until a serum concentration of 40 ng/mL of 25(OH)D3 was reached [109]. </plain></SENT>
<SENT sid="192" pm="."><plain>After 24 weeks, a significant reduction of the CDAI and an improvement of the IBDQ score were observed. </plain></SENT>
<SENT sid="193" pm="."><plain>No differences were observed for CRP, erythrocyte sedimentation rate (ESR), TNF-α, IL-17, IL-10, and vascular endothelial growth factor (VEGF). </plain></SENT>
<SENT sid="194" pm="."><plain>Data on serum calcium levels were not reported. </plain></SENT>
</text></p><p><text><SENT sid="195" pm="."><plain>In this last paragraph, the therapeutic effects of vitamin D supplementation on disease activity mainly given to patients in remission yielded modest results; the daily administered dose ranged in these studies between 1000 and 5000 IU, with an increase of serum vitamin D levels but apparently without hypercalcemia. </plain></SENT>
</text></p></sec><SecTag type="CONCL"><sec id="sec9"><title><text><SENT sid="196" pm="."><plain>9. </plain></SENT>
<SENT sid="197" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="198" pm="."><plain>Literature data highlighting the importance of vitamin D in different aspects of immune regulation, for example, in chronic immune-mediated diseases and cancer, suggest considering this metabolite not simply as a vitamin involved in bone and calcium homeostasis but as an autocrine mediator with an active role in numerous physiological processes, particularly in the innate immune system. </plain></SENT>
<SENT sid="199" pm="."><plain>Since most studies concerning the calcium status in IBD yielded contradictory data, in the most recent literature, the discussion has focused on the possible role of vitamin D as a risk factor for the onset and evolution of gut inflammation. </plain></SENT>
<SENT sid="200" pm="."><plain>The potential role of 25(OH)2D as negative acute phase reactant has yet to be proven in IBD but may explain its frequently reduced levels in active disease. </plain></SENT>
<SENT sid="201" pm="."><plain>Besides lower vitamin D levels due to reduced UV exposure, genetic induced loss of function of VDR may contribute to defects involving vitamin D pathways. </plain></SENT>
<SENT sid="202" pm="."><plain>It has been shown in VDR KO animals that this deletion profoundly alters innate immune response and the gut microbiota. </plain></SENT>
<SENT sid="203" pm="."><plain>Further studies in this field are needed to provide more insight in the link between vitamin D/VDR and bowel inflammation. </plain></SENT>
</text></p><p><text><SENT sid="204" pm="."><plain>Simple vitamin D supplementation does not seem to lead to significant improvement of the clinical course of IBD but may be indicated for a subset of patients. </plain></SENT>
<SENT sid="205" pm="."><plain>Vitamin D synthetic analogues of vitamin D seem to be more promising, at least in animal studies and in ex vivo experiments. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgment</title><p><text4fund><text><SENT sid="206" pm="."><plain>The authors wish to thank Trays Ricciardi for language editing. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="COMP_INT"><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec></SecTag><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="207" pm="."><plain>1JonesG.StrugnellS. </plain></SENT>
<SENT sid="208" pm="."><plain>A.DeLucaH. </plain></SENT>
<SENT sid="209" pm="."><plain>F.Current understanding of the molecular actions of vitamin DPhysiological Reviews1998784119312312-s2.0-00317551689790574 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="210" pm="."><plain>2NarulaN.MarshallJ. </plain></SENT>
<SENT sid="211" pm="."><plain>K.Management of inflammatory bowel disease with vitamin D: beyond bone healthJournal of Crohn's &amp; Colitis20126439740410.1016/j.crohns.2011.10.0152-s2.0-84860210326 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="212" pm="."><plain>3HolickM. </plain></SENT>
<SENT sid="213" pm="."><plain>F.ChenT. </plain></SENT>
<SENT sid="214" pm="."><plain>C.LuZ.SauterE.Vitamin D and skin physiology: a D-lightful storyJournal of Bone and Mineral Research2007222V28V3310.1359/jbmr.07s2112-s2.0-3974911314218290718 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="215" pm="."><plain>4BaekeF.EttenE. </plain></SENT>
<SENT sid="216" pm="."><plain>V.GysemansC.OverberghL.MathieuC.Vitamin D signaling in immune-mediated disorders: evolving insights and therapeutic opportunitiesMolecular Aspects of Medicine200829637638710.1016/j.mam.2008.05.0042-s2.0-5614910148018621414 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="217" pm="."><plain>5PikeJ. </plain></SENT>
<SENT sid="218" pm="."><plain>W.MeyerM. </plain></SENT>
<SENT sid="219" pm="."><plain>B.The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D3Rheumatic Disease Clinics of North America2012381132710.1016/j.rdc.2012.03.0042-s2.0-8485996271422525840 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="220" pm="."><plain>6RamanM.MilestoneA. </plain></SENT>
<SENT sid="221" pm="."><plain>N.WaltersJ. </plain></SENT>
<SENT sid="222" pm="."><plain>R. </plain></SENT>
<SENT sid="223" pm="."><plain>F.HarA. </plain></SENT>
<SENT sid="224" pm="."><plain>L.GhoshS.Vitamin D and gastrointestinal diseases: inflammatory bowel disease and colorectal cancerTherapeutic Advances in Gastroenterology201141496210.1177/1756283x103778202-s2.0-8005172366621317994 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="225" pm="."><plain>7ChunR. </plain></SENT>
<SENT sid="226" pm="."><plain>F.LiuP. </plain></SENT>
<SENT sid="227" pm="."><plain>T.ModlinR. </plain></SENT>
<SENT sid="228" pm="."><plain>L.AdamsJ. </plain></SENT>
<SENT sid="229" pm="."><plain>S.HewisonM.Impact of vitamin D on immune function: lessons learned from genome-wide analysisFrontiers in Physiology20145, article 1511510.3389/fphys.2014.0015124478726 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="230" pm="."><plain>8SunJ.Vitamin D and mucosal immune functionCurrent Opinion in Gastroenterology20102665915952-s2.0-7795848585310.1097/MOG.0b013e32833d4b9f20639756 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="231" pm="."><plain>9ChenJ.BruceD.CantornaM. </plain></SENT>
<SENT sid="232" pm="."><plain>T.Vitamin D receptor expression controls proliferation of naïve CD8+ T cells and development of CD8 mediated gastrointestinal inflammationBMC Immunology20141561112-s2.0-8489366244610.1186/1471-2172-15-624423010 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="233" pm="."><plain>10KühneH.SchutkowskiA.WeinholzS.Vitamin D receptor regulates intestinal proteins involved in cell proliferation, migration and stress responseLipids in Health and Disease201413, article 5110.1186/1476-511x-13-512-s2.0-84899423943 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="234" pm="."><plain>11van EttenE.MathieuC.Immunoregulation by 1,25-dihydroxyvitamin D3: basic conceptsThe Journal of Steroid Biochemistry and Molecular Biology2005971-29310110.1016/j.jsbmb.2005.06.0022-s2.0-2754449968616046118 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="235" pm="."><plain>12TangJ.ZhouR.LugerD.Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector responseJournal of Immunology200918284624463210.4049/jimmunol.08015432-s2.0-65249120937 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="236" pm="."><plain>13JefferyL. </plain></SENT>
<SENT sid="237" pm="."><plain>E.BurkeF.MuraM.1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3Journal of Immunology200918395458546710.4049/jimmunol.08032172-s2.0-77951253745 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="238" pm="."><plain>14HausslerM. </plain></SENT>
<SENT sid="239" pm="."><plain>R.HausslerC. </plain></SENT>
<SENT sid="240" pm="."><plain>A.WhitfieldG. </plain></SENT>
<SENT sid="241" pm="."><plain>K.The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the ‘Fountain of Youth’ to mediate healthful agingThe Journal of Steroid Biochemistry and Molecular Biology20101211-2889710.1016/j.jsbmb.2010.03.0192-s2.0-7795476126020227497 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="242" pm="."><plain>15ArtazaJ. </plain></SENT>
<SENT sid="243" pm="."><plain>N.SiradF.FerriniM. </plain></SENT>
<SENT sid="244" pm="."><plain>G.NorrisK. </plain></SENT>
<SENT sid="245" pm="."><plain>C.1,25(OH)2 vitamin D3 inhibits cell proliferation by promoting cell cycle arrest without inducing apoptosis and modifies cell morphology of mesenchymal multipotent cellsThe Journal of Steroid Biochemistry and Molecular Biology20101191-273832-s2.0-7674911936210.1016/j.jsbmb.2010.01.00120064609 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="246" pm="."><plain>16BischofM. </plain></SENT>
<SENT sid="247" pm="."><plain>G.RedlichK.SchillerC.Growth inhibitory effects on human colon adenocarcinoma-derived Caco-2 cells and calcemic potential of 1α,25- dihydroxyvitamin D3 analogs: structure-function relationshipsJournal of Pharmacology and Experimental Therapeutics19952753125412602-s2.0-00295544238531089 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="248" pm="."><plain>17CrossH. </plain></SENT>
<SENT sid="249" pm="."><plain>S.PavelkaM.SlavikJ.PeterlikM.Growth control of human colon cancer cells by vitamin D and calcium in vitroJournal of the National Cancer Institute199284171355136210.1093/jnci/84.17.13552-s2.0-00268021891495105 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="250" pm="."><plain>18HugotJ. </plain></SENT>
<SENT sid="251" pm="."><plain>P.ChamaillardM.ZoualiH.Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's diseaseNature2001411683759960310.1038/3507910711385576 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="252" pm="."><plain>19InoharaN.OguraY.FontalbaA.Host recognition of bacterial muramyl dipeptide mediated through NOD2. </plain></SENT>
<SENT sid="253" pm="."><plain>Implications for Crohn's diseaseThe Journal of Biological Chemistry200327885509551210.1074/jbc.c2006732002-s2.0-003745866512514169 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="254" pm="."><plain>20WangT. </plain></SENT>
<SENT sid="255" pm="."><plain>T.DabbasB.LaperriereD.Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn diseaseThe Journal of Biological Chemistry201028542227223110.1074/jbc.c109.0712252-s2.0-7744911937519948723 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="256" pm="."><plain>21WuS.ZhangY. </plain></SENT>
<SENT sid="257" pm="."><plain>G.LuR.Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitisGut201410.1136/gutjnl-2014-307436 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="258" pm="."><plain>22VerwayM.BehrM. </plain></SENT>
<SENT sid="259" pm="."><plain>A.WhiteJ. </plain></SENT>
<SENT sid="260" pm="."><plain>H.Vitamin D, NOD2, autophagy and Crohn's diseaseExpert Review of Clinical Immunology20106450550810.1586/eci.10.312-s2.0-7795440337420594120 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="261" pm="."><plain>23SimmonsJ. </plain></SENT>
<SENT sid="262" pm="."><plain>D.MullighanC.WelshK. </plain></SENT>
<SENT sid="263" pm="."><plain>I.JewellD. </plain></SENT>
<SENT sid="264" pm="."><plain>P.Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibilityGut200047221121410.1136/gut.47.2.2112-s2.0-003393229110896912 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="265" pm="."><plain>24MartinK.RadlmayrM.BorchersR.HeinzlmannM.FolwacznyC.Candidate genes colocalized to linkage regions in inflammatory bowel diseaseDigestion200266212112610.1159/0000655922-s2.0-003643422412428072 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="266" pm="."><plain>25KöstnerK.DenzerN.MüllerC. </plain></SENT>
<SENT sid="267" pm="."><plain>S. </plain></SENT>
<SENT sid="268" pm="."><plain>L.KleinR.TilgenW.ReichrathJ.The relevance of Vitamin D Receptor (VDR) gene polymorphisms for cancer: a review of the literatureAnticancer Research2009299351135362-s2.0-6854911880119667145 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="269" pm="."><plain>26XuY.HeB.PanY.Systematic review and meta-analysis on vitamin D receptor polymorphisms and cancer riskTumour Biology20143554153416910.1007/s13277-013-1544-y24408013 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="270" pm="."><plain>27TizaouiK.BerraiesA.HamdiB.KaabachiW.HamzaouiK.HamzaouiA.Association of vitamin d receptor gene polymorphisms with asthma risk: systematic review and updated meta-analysis of case-control studiesLung2014192695596510.1007/s00408-014-9648-825267113 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="271" pm="."><plain>28SantoroD.CaccamoD.GagliostroG.Vitamin D metabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patientsJournal of Nephrology20132646366442-s2.0-8488010602110.5301/jn.500020322976524 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="272" pm="."><plain>29HughesD. </plain></SENT>
<SENT sid="273" pm="."><plain>J.McManusR.NearyP.O'MorainC.O'SullivanM.Common variation in the vitamin D receptor gene and risk of inflammatory bowel disease in an Irish case-control studyEuropean Journal of Gastroenterology &amp; Hepatology201123980781210.1097/meg.0b013e328349283e2-s2.0-8005172075921818054 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="274" pm="."><plain>30PluskiewiczW.ZdrzałekJ.KarasekD.Spine bone mineral density and VDR polymorphism in subjects with ulcerative colitisJournal of Bone and Mineral Metabolism200927556757310.1007/s00774-009-0072-82-s2.0-6894913014819365702 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="275" pm="."><plain>31PeiF. </plain></SENT>
<SENT sid="276" pm="."><plain>H.WangY. </plain></SENT>
<SENT sid="277" pm="."><plain>J.GaoS. </plain></SENT>
<SENT sid="278" pm="."><plain>L.Vitamin D receptor gene polymorphism and ulcerative colitis susceptibility in Han ChineseJournal of Digestive Diseases201112290982-s2.0-7995266896510.1111/j.1751-2980.2011.00483.x21401893 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="279" pm="."><plain>32XiaS. </plain></SENT>
<SENT sid="280" pm="."><plain>L.YuL. </plain></SENT>
<SENT sid="281" pm="."><plain>Q.ChenH.Association of vitamin D receptor gene polymorphisms with the susceptibility to ulcerative colitis in patients from Southeast ChinaJournal of Receptors and Signal Transduction201410.3109/10799893.2014.975248 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="282" pm="."><plain>33LuoY. </plain></SENT>
<SENT sid="283" pm="."><plain>Y.ShuX. </plain></SENT>
<SENT sid="284" pm="."><plain>L.ZhaoH.YuJ. </plain></SENT>
<SENT sid="285" pm="."><plain>D.MaM.ChenJ.Association between vitamin D receptor gene polymorphisms and pediatric Crohn's disease in China: A study based on gene sequencingZhongguo Dang Dai Er Ke Za Zhi201315111006100810.7499/j.issn.1008-8830.2013.11.0192-s2.0-8489320820724229599 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="286" pm="."><plain>34NobleC. </plain></SENT>
<SENT sid="287" pm="."><plain>L.McCulloughJ.HoW.Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel diseaseAlimentary Pharmacology &amp; Therapeutics20082775885962-s2.0-3984908463810.1111/j.1365-2036.2008.03599.x18194505 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="288" pm="."><plain>35BentleyR. </plain></SENT>
<SENT sid="289" pm="."><plain>W.KeownD.MerrimanT. </plain></SENT>
<SENT sid="290" pm="."><plain>R.Vitamin D receptor gene polymorphism associated with inflammatory bowel disease in New Zealand malesAlimentary Pharmacology and Therapeutics201133785585610.1111/j.1365-2036.2011.04588.x2-s2.0-7995225651421366629 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="291" pm="."><plain>36Dresner-PollakR.AckermanZ.EliakimR.KarbanA.ChowersY.FidderH. </plain></SENT>
<SENT sid="292" pm="."><plain>H.The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patientsGenetic Testing20048441742010.1089/gte.2004.8.4172-s2.0-1144426487515684874 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="293" pm="."><plain>37NaderiN.FarnoodA.HabibiM.Association of vitamin D receptor gene polymorphisms in Iranian patients with inflammatory bowel diseaseJournal of Gastroenterology and Hepatology200823121816182210.1111/j.1440-1746.2008.05525.x2-s2.0-5704912104918752562 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="294" pm="."><plain>38XueL.-N.XuK.-Q.ZhangW.WangQ.WuJ.WangX.-Y.Associations between vitamin D receptor polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysisInflammatory Bowel Diseases2013191546010.1002/ibd.229662-s2.0-8487371608222467262 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="295" pm="."><plain>39WangL.WangZ. </plain></SENT>
<SENT sid="296" pm="."><plain>T.HuJ. </plain></SENT>
<SENT sid="297" pm="."><plain>J.FanR.ZhouJ.ZhongJ.Polymorphisms of the vitamin D receptor gene and the risk of inflammatory bowel disease: a meta-analysisGenetics and Molecular Research2014132259826102-s2.0-8489843095310.4238/2014.april.8.224782048 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="298" pm="."><plain>40CarvalhoA. </plain></SENT>
<SENT sid="299" pm="."><plain>Y. </plain></SENT>
<SENT sid="300" pm="."><plain>O. </plain></SENT>
<SENT sid="301" pm="."><plain>M.BishopK. </plain></SENT>
<SENT sid="302" pm="."><plain>S.HanD. </plain></SENT>
<SENT sid="303" pm="."><plain>Y.The role of vitamin D level and related single nucleotide polymorphisms in Crohn's diseaseNutrients20135103898390910.3390/nu51038982-s2.0-8488467985424084050 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="304" pm="."><plain>41JonesG.StewartG.Association of PHF11 polymorphisms with asthma and allergyThorax201065765966010.1136/thx.2009.1245112-s2.0-7795528308120627928 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="305" pm="."><plain>42ElorantaJ. </plain></SENT>
<SENT sid="306" pm="."><plain>J.WengerC.MwinyiJ.Association of a common vitamin D-binding protein polymorphism with inflammatory bowel diseasePharmacogenetics and Genomics20112195595642-s2.0-8005178397710.1097/FPC.0b013e328348f70c21832969 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="307" pm="."><plain>43SonnenbergA.EhmsH.SonnenbergG. </plain></SENT>
<SENT sid="308" pm="."><plain>E.StrohmeyerG.25-Hydroxycholecalciferol serum levels in patients with Crohn's diseaseActa Hepato-Gastroenterologica19772442932952-s2.0-0017744867906778 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="309" pm="."><plain>44Nic SuibhneT.CoxG.HealyM.O'MorainC.O'SullivanM.Vitamin D deficiency in Crohn's disease: prevalence, risk factors and supplement use in an outpatient settingJournal of Crohn's &amp; Colitis20126218218810.1016/j.crohns.2011.08.0022-s2.0-84856744222 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="310" pm="."><plain>45ArdizzoneS.BollaniS.BetticaP.BevilacquaM.MolteniP.PorroG. </plain></SENT>
<SENT sid="311" pm="."><plain>B.Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitisJournal of Internal Medicine20002471637010.1046/j.1365-2796.2000.00582.x2-s2.0-003397930910672132 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="312" pm="."><plain>46TajikaM.MatsuuraA.NakamuraT.Risk factors for vitamin D deficiency in patients with Crohn's diseaseJournal of Gastroenterology20043965275332-s2.0-324288039515235869 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="313" pm="."><plain>47AbreuM. </plain></SENT>
<SENT sid="314" pm="."><plain>T.KantorovichY.VasiliauskasE. </plain></SENT>
<SENT sid="315" pm="."><plain>A.Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral densityGut20045381129113610.1136/gut.2003.0366572-s2.0-324266688915247180 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="316" pm="."><plain>48de BruynJ. </plain></SENT>
<SENT sid="317" pm="."><plain>R.van HeeckerenR.PonsioenC. </plain></SENT>
<SENT sid="318" pm="."><plain>Y.Vitamin D deficiency in Crohn's disease and healthy controls: a prospective case-control study in the NetherlandsJournal of Crohn's and Colitis20148101267127310.1016/j.crohns.2014.03.0042-s2.0-84896415303 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="319" pm="."><plain>49VeitL. </plain></SENT>
<SENT sid="320" pm="."><plain>E.MarandaL.FongJ.NwosuB. </plain></SENT>
<SENT sid="321" pm="."><plain>U.The vitamin D status in inflammatory bowel diseasePLoS ONE201497e10158310.1371/journal.pone.0101583 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="322" pm="."><plain>50HarriesA. </plain></SENT>
<SENT sid="323" pm="."><plain>D.BrownR.HeatleyR. </plain></SENT>
<SENT sid="324" pm="."><plain>V.WilliamsL. </plain></SENT>
<SENT sid="325" pm="."><plain>A.WoodheadS.RhodesJ.Vitamin D status in Crohn's disease: association with nutrition and disease activityGut198526111197120310.1136/gut.26.11.11972-s2.0-00223872983877663 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="326" pm="."><plain>51RudnickiM.FrølichA.TransbølI.Inappropriate hypercalcitriolemia in ileum-resected patients with Crohn's diseaseMineral and Electrolyte Metabolism199218152552-s2.0-00264560721406505 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="327" pm="."><plain>52JosephA. </plain></SENT>
<SENT sid="328" pm="."><plain>J.GeorgeB.PulimoodA. </plain></SENT>
<SENT sid="329" pm="."><plain>B.SeshadriM. </plain></SENT>
<SENT sid="330" pm="."><plain>S.ChackoA.25 (OH) vitamin D level in Crohn's disease: association with sun exposure &amp; disease activityIndian Journal of Medical Research200913021331372-s2.0-7034953869519797809 </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="331" pm="."><plain>53McCarthyD.DugganP.O'BrienM.Seasonality of vitamin D status and bone turnover in patients with Crohn's diseaseAlimentary Pharmacology &amp; Therapeutics20052191073108310.1111/j.1365-2036.2005.02446.x2-s2.0-1844437676315854168 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="332" pm="."><plain>54El-MataryW.SikoraS.SpadyD.Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel diseaseDigestive Diseases and Sciences201156382582910.1007/s10620-010-1380-52-s2.0-7995244292020725784 </plain></SENT>
</text></ref><ref id="B55"><text><SENT sid="333" pm="."><plain>55SilvennoinenJ.Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel diseaseJournal of Internal Medicine1996239213113710.1046/j.1365-2796.1996.420765000.x2-s2.0-00300225728568480 </plain></SENT>
</text></ref><ref id="B56"><text><SENT sid="334" pm="."><plain>56GilmanJ.ShanahanF.CashmanK. </plain></SENT>
<SENT sid="335" pm="."><plain>D.Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn's disease and ulcerative colitisAlimentary Pharmacology &amp; Therapeutics2006237100710162-s2.0-3364504589510.1111/j.1365-2036.2006.02835.x16573803 </plain></SENT>
</text></ref><ref id="B57"><text><SENT sid="336" pm="."><plain>57de SouzaH. </plain></SENT>
<SENT sid="337" pm="."><plain>N.LoraF. </plain></SENT>
<SENT sid="338" pm="."><plain>L.KulakC. </plain></SENT>
<SENT sid="339" pm="."><plain>A. </plain></SENT>
<SENT sid="340" pm="."><plain>M.MañasN. </plain></SENT>
<SENT sid="341" pm="."><plain>C. </plain></SENT>
<SENT sid="342" pm="."><plain>P.AmaranteH. </plain></SENT>
<SENT sid="343" pm="."><plain>M. </plain></SENT>
<SENT sid="344" pm="."><plain>B.BorbaV. </plain></SENT>
<SENT sid="345" pm="."><plain>Z. </plain></SENT>
<SENT sid="346" pm="."><plain>C.Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral densityArquivos Brasileiros de Endocrinologia e Metabologia200852468469110.1590/s0004-273020080004000152-s2.0-4724914808118604382 </plain></SENT>
</text></ref><ref id="B58"><text><SENT sid="347" pm="."><plain>58LeslieW. </plain></SENT>
<SENT sid="348" pm="."><plain>D.MillerN.RogalaL.BernsteinC. </plain></SENT>
<SENT sid="349" pm="."><plain>N.Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort StudyAmerican Journal of Gastroenterology200810361451145910.1111/j.1572-0241.2007.01753.x2-s2.0-4494917479618422819 </plain></SENT>
</text></ref><ref id="B59"><text><SENT sid="350" pm="."><plain>59UlitskyA.AnanthakrishnanA. </plain></SENT>
<SENT sid="351" pm="."><plain>N.NaikA.Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of lifeJournal of Parenteral and Enteral Nutrition201135330831610.1177/01486071103812672-s2.0-7995565307221527593 </plain></SENT>
</text></ref><ref id="B60"><text><SENT sid="352" pm="."><plain>60HassanV.HassanS.Seyed-JavadP.Association between serum 25 (OH) vitamin D concentrations and inflammatory bowel diseases (IBDS) activityMedical Journal of Malaysia201368134382-s2.0-8487443123823466764 </plain></SENT>
</text></ref><ref id="B61"><text><SENT sid="353" pm="."><plain>61AlkhouriR. </plain></SENT>
<SENT sid="354" pm="."><plain>H.HashmiH.BakerR. </plain></SENT>
<SENT sid="355" pm="."><plain>D.GelfondD.BakerS. </plain></SENT>
<SENT sid="356" pm="."><plain>S.Vitamin and mineral status in patients with inflammatory bowel diseaseJournal of Pediatric Gastroenterology and Nutrition2013561899210.1097/MPG.0b013e31826a105d2-s2.0-8487233243822832510 </plain></SENT>
</text></ref><ref id="B62"><text><SENT sid="357" pm="."><plain>62PappaH. </plain></SENT>
<SENT sid="358" pm="."><plain>M.GordonC. </plain></SENT>
<SENT sid="359" pm="."><plain>M.SaslowskyT. </plain></SENT>
<SENT sid="360" pm="."><plain>M.Vitamin D status in children and young adults with inflammatory bowel diseasePediatrics20061185195019612-s2.0-3375095890510.1542/peds.2006-084117079566 </plain></SENT>
</text></ref><ref id="B63"><text><SENT sid="361" pm="."><plain>63JahnsenJ.FalchJ. </plain></SENT>
<SENT sid="362" pm="."><plain>A.MowinckelP.AadlandE.Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel diseaseScandinavian Journal of Gastroenterology200237219219910.1080/0036552027534168762-s2.0-003615295011843057 </plain></SENT>
</text></ref><ref id="B64"><text><SENT sid="363" pm="."><plain>64KuwabaraA.TanakaK.TsugawaN.High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel diseaseOsteoporosis International20092069359422-s2.0-6734914232410.1007/s00198-008-0764-218825300 </plain></SENT>
</text></ref><ref id="B65"><text><SENT sid="364" pm="."><plain>65EzzatY.HamdyK.The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseasesInternational Journal of Rheumatic Diseases201013325926510.1111/j.1756-185x.2010.01542.x2-s2.0-7795539698720704624 </plain></SENT>
</text></ref><ref id="B66"><text><SENT sid="365" pm="."><plain>66AtiaA.MurthyR.BaileyB. </plain></SENT>
<SENT sid="366" pm="."><plain>A.Vitamin D Status in Veterans with inflammatory bowel disease: relationship to Health care costs and servicesMilitary Medicine2011176671171410.7205/milmed-d-10-003712-s2.0-8005162182321702395 </plain></SENT>
</text></ref><ref id="B67"><text><SENT sid="367" pm="."><plain>67HessovI.MosekildeL.MelsenF.Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's diseaseScandinavian Journal of Gastroenterology19841956916962-s2.0-00211345526332369 </plain></SENT>
</text></ref><ref id="B68"><text><SENT sid="368" pm="."><plain>68NakajimaS.IijimaH.EgawaS.Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel diseaseNutrition20112710102310282-s2.0-8005274110610.1016/j.nut.2010.10.02121482072 </plain></SENT>
</text></ref><ref id="B69"><text><SENT sid="369" pm="."><plain>69LaaksoS.ValtaH.VerkasaloM.Toiviainen-SaloS.ViljakainenH.MäkitieO.Impaired bone health in inflammatory bowel disease: a case-control study in 80 pediatric patientsCalcified Tissue International201291212113010.1007/s00223-012-9617-22-s2.0-8486597463322729560 </plain></SENT>
</text></ref><ref id="B70"><text><SENT sid="370" pm="."><plain>70DriscollR. </plain></SENT>
<SENT sid="371" pm="."><plain>H.Jr.MeredithS. </plain></SENT>
<SENT sid="372" pm="."><plain>C.SitrinM.RosenbergI. </plain></SENT>
<SENT sid="373" pm="."><plain>H.Vitamin D deficiency and bone disease in patients with Crohn's diseaseGastroenterology1982836125212582-s2.0-00203853996982188 </plain></SENT>
</text></ref><ref id="B71"><text><SENT sid="374" pm="."><plain>71VogelsangH.SchöflR.TillingerW.FerenciP.GanglA.25-Hydroxyvitamin D absorption in patients with Crohn's disease and with pancreatic insufficiencyWiener Klinische Wochenschrift1997109176786822-s2.0-00309874899331957 </plain></SENT>
</text></ref><ref id="B72"><text><SENT sid="375" pm="."><plain>72SchoonE. </plain></SENT>
<SENT sid="376" pm="."><plain>J.MüllerM. </plain></SENT>
<SENT sid="377" pm="."><plain>C. </plain></SENT>
<SENT sid="378" pm="."><plain>A.VermeerC.SchurgersL. </plain></SENT>
<SENT sid="379" pm="."><plain>J.BrummerR.-J. </plain></SENT>
<SENT sid="380" pm="."><plain>M.StockbrüggerR. </plain></SENT>
<SENT sid="381" pm="."><plain>W.Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease?Gut20014844734772-s2.0-003508000110.1136/gut.48.4.47311247890 </plain></SENT>
</text></ref><ref id="B73"><text><SENT sid="382" pm="."><plain>73HaderslevK. </plain></SENT>
<SENT sid="383" pm="."><plain>V.JeppesenP. </plain></SENT>
<SENT sid="384" pm="."><plain>B.SorensenH. </plain></SENT>
<SENT sid="385" pm="."><plain>A.MortensenP. </plain></SENT>
<SENT sid="386" pm="."><plain>B.StaunM.Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resectionGut200352565365810.1136/gut.52.5.6532-s2.0-003830010712692048 </plain></SENT>
</text></ref><ref id="B74"><text><SENT sid="387" pm="."><plain>74GilmanJ.ShanahanF.CashmanK. </plain></SENT>
<SENT sid="388" pm="."><plain>D.Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D useEuropean Journal of Clinical Nutrition200660788989610.1038/sj.ejcn.16023952-s2.0-3374569885116493452 </plain></SENT>
</text></ref><ref id="B75"><text><SENT sid="389" pm="."><plain>75LevinA. </plain></SENT>
<SENT sid="390" pm="."><plain>D.WadheraV.LeachS. </plain></SENT>
<SENT sid="391" pm="."><plain>T.Vitamin D deficiency in children with inflammatory bowel diseaseDigestive Diseases and Sciences201156383083610.1007/s10620-010-1544-32-s2.0-7995245114321222159 </plain></SENT>
</text></ref><ref id="B76"><text><SENT sid="392" pm="."><plain>76KiniG. </plain></SENT>
<SENT sid="393" pm="."><plain>P.YoungB.HerbisonP.SchultzM.Does seasonal level of serum 25-OH vitamin D correlate with the activity of Crohn’s disease?New Zealand Medical Journal20141271394515924929571 </plain></SENT>
</text></ref><ref id="B82"><text><SENT sid="394" pm="."><plain>77FarrayeF. </plain></SENT>
<SENT sid="395" pm="."><plain>A.NimitphongH.StucchiA.Use of a novel vitamin D bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent Crohn's diseaseInflammatory Bowel Diseases201117102116212110.1002/ibd.215952-s2.0-8005272242921910173 </plain></SENT>
</text></ref><ref id="B77"><text><SENT sid="396" pm="."><plain>78SentongoT. </plain></SENT>
<SENT sid="397" pm="."><plain>A.SemaeoE. </plain></SENT>
<SENT sid="398" pm="."><plain>J.StettlerN.PiccoliD. </plain></SENT>
<SENT sid="399" pm="."><plain>A.StallingsV. </plain></SENT>
<SENT sid="400" pm="."><plain>A.ZemelB. </plain></SENT>
<SENT sid="401" pm="."><plain>S.Vitamin D status in children, adolescents, and young adults with Crohn diseaseThe American Journal of Clinical Nutrition2002765107710812-s2.0-003682906712399281 </plain></SENT>
</text></ref><ref id="B78"><text><SENT sid="402" pm="."><plain>79SiffledeenJ. </plain></SENT>
<SENT sid="403" pm="."><plain>S.SiminoskiK.SteinhartH.GreenbergG.FedorakR. </plain></SENT>
<SENT sid="404" pm="."><plain>N.The frequency of vitamin D deficiency in adults with Crohn's diseaseCanadian Journal of Gastroenterology20031784734782-s2.0-014214918712945007 </plain></SENT>
</text></ref><ref id="B79"><text><SENT sid="405" pm="."><plain>80PappaH. </plain></SENT>
<SENT sid="406" pm="."><plain>M.LangereisE. </plain></SENT>
<SENT sid="407" pm="."><plain>J.GrandR. </plain></SENT>
<SENT sid="408" pm="."><plain>J.GordonC. </plain></SENT>
<SENT sid="409" pm="."><plain>M.Prevalence and risk factors for hypovitaminosis D in young patients with inflammatory bowel diseaseJournal of Pediatric Gastroenterology and Nutrition20115343613642-s2.0-8095517960710.1097/MPG.0b013e3182250b3e21613964 </plain></SENT>
</text></ref><ref id="B80"><text><SENT sid="410" pm="."><plain>81AnanthakrishnanA. </plain></SENT>
<SENT sid="411" pm="."><plain>N.CaganA.GainerV. </plain></SENT>
<SENT sid="412" pm="."><plain>S.Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's diseaseInflammatory Bowel Diseases20131991921192710.1097/MIB.0b013e3182902ad92-s2.0-8488464478923751398 </plain></SENT>
</text></ref><ref id="B81"><text><SENT sid="413" pm="."><plain>82HlavatyT.KrajcovicovaA.KollerT.Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseasesWorld Journal of Gastroenterology20142042157871579610.3748/wjg.v20.i42.1578725400464 </plain></SENT>
</text></ref><ref id="B83"><text><SENT sid="414" pm="."><plain>83Peyrin-BirouletL.OussalahA.BigardM.-A.Crohn's disease: the hot hypothesisMedical Hypotheses2009731949610.1016/j.mehy.2009.01.0222-s2.0-6734909219719269107 </plain></SENT>
</text></ref><ref id="B84"><text><SENT sid="415" pm="."><plain>84de BruynJ. </plain></SENT>
<SENT sid="416" pm="."><plain>R.van HeeckerenR.PonsioenC. </plain></SENT>
<SENT sid="417" pm="."><plain>Y.Vitamin D deficiency in Crohn's disease and healthy controls: a prospective case-control study in the NetherlandsJournal of Crohn's &amp; Colitis20148101267127310.1016/j.crohns.2014.03.004 </plain></SENT>
</text></ref><ref id="B85"><text><SENT sid="418" pm="."><plain>85NerichV.JantchouP.Boutron-RuaultM.-C.Low exposure to sunlight is a risk factor for Crohn's diseaseAlimentary Pharmacology and Therapeutics201133894094510.1111/j.1365-2036.2011.04601.x2-s2.0-7995279208821332762 </plain></SENT>
</text></ref><ref id="B86"><text><SENT sid="419" pm="."><plain>86JantchouP.Clavel-ChapelonF.RacineA.KvaskoffM.CarbonnelF.Boutron-RuaultM.-C.High residential sun exposure is associated with a low risk of incident Crohn's disease in the prospective E3N cohortInflammatory Bowel Diseases2014201758110.1097/01.MIB.0000436275.12131.4f2-s2.0-8489367812724247650 </plain></SENT>
</text></ref><ref id="B87"><text><SENT sid="420" pm="."><plain>87LimketkaiB. </plain></SENT>
<SENT sid="421" pm="."><plain>N.BaylessT. </plain></SENT>
<SENT sid="422" pm="."><plain>M.BrantS. </plain></SENT>
<SENT sid="423" pm="."><plain>R.HutflessS. </plain></SENT>
<SENT sid="424" pm="."><plain>M.Lower regional and temporal ultraviolet exposure is associated with increased rates and severity of inflammatory bowel disease hospitalisationAlimentary Pharmacology &amp; Therapeutics201440550851710.1111/apt.1284524943863 </plain></SENT>
</text></ref><ref id="B88"><text><SENT sid="425" pm="."><plain>88GovaniS. </plain></SENT>
<SENT sid="426" pm="."><plain>M.HigginsP. </plain></SENT>
<SENT sid="427" pm="."><plain>D. </plain></SENT>
<SENT sid="428" pm="."><plain>R.StidhamR. </plain></SENT>
<SENT sid="429" pm="."><plain>W.MontainS. </plain></SENT>
<SENT sid="430" pm="."><plain>J.WaljeeA. </plain></SENT>
<SENT sid="431" pm="."><plain>K.Increased ultraviolet light exposure is associated with reduced risk of inpatient surgery among patients with Crohn's diseaseJournal of Crohn's and Colitis201591778110.1093/ecco-jcc/jju002 </plain></SENT>
</text></ref><ref id="B89"><text><SENT sid="432" pm="."><plain>89AnanthakrishnanA. </plain></SENT>
<SENT sid="433" pm="."><plain>N.KhaliliH.HiguchiL. </plain></SENT>
<SENT sid="434" pm="."><plain>M.Higher predicted vitamin D status is associated with reduced risk of crohn's diseaseGastroenterology2012142348248910.1053/j.gastro.2011.11.0402-s2.0-8485753398622155183 </plain></SENT>
</text></ref><ref id="B90"><text><SENT sid="435" pm="."><plain>90GargM.RosellaO.LubelJ. </plain></SENT>
<SENT sid="436" pm="."><plain>S.GibsonP. </plain></SENT>
<SENT sid="437" pm="."><plain>R.Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel diseaseInflammatory Bowel Diseases20131912263426432-s2.0-8488834522810.1097/01.MIB.0000436957.77533.b224105392 </plain></SENT>
</text></ref><ref id="B91"><text><SENT sid="438" pm="."><plain>91AnanthakrishnanA. </plain></SENT>
<SENT sid="439" pm="."><plain>N.CaganA.GainerV. </plain></SENT>
<SENT sid="440" pm="."><plain>S.Higher plasma vitamin D is associated with reduced risk of Clostridium difficile infection in patients with inflammatory bowel diseasesAlimentary Pharmacology and Therapeutics201439101136114210.1111/apt.127062-s2.0-8489885916324641590 </plain></SENT>
</text></ref><ref id="B92"><text><SENT sid="441" pm="."><plain>92ZatorZ. </plain></SENT>
<SENT sid="442" pm="."><plain>A.CantuS. </plain></SENT>
<SENT sid="443" pm="."><plain>M.KonijetiG. </plain></SENT>
<SENT sid="444" pm="."><plain>G.Pretreatment 25-hydroxyvitamin D levels and durability of anti–tumor necrosis factor-α therapy in inflammatory bowel diseasesJournal of Parenteral and Enteral Nutrition201438338539110.1177/014860711350400224088707 </plain></SENT>
</text></ref><ref id="B93"><text><SENT sid="445" pm="."><plain>93HamM.LonghiM. </plain></SENT>
<SENT sid="446" pm="."><plain>S.LahiffC.CheifetzA.RobsonS.MossA. </plain></SENT>
<SENT sid="447" pm="."><plain>C.Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatmentInflammatory Bowel Diseases201420585686010.1097/mib.000000000000001624681654 </plain></SENT>
</text></ref><ref id="B94"><text><SENT sid="448" pm="."><plain>94ReidD.TooleB. </plain></SENT>
<SENT sid="449" pm="."><plain>J.KnoxS.The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplastyThe American Journal of Clinical Nutrition20119351006101110.3945/ajcn.110.0084902-s2.0-7995538423221411617 </plain></SENT>
</text></ref><ref id="B95"><text><SENT sid="450" pm="."><plain>95WaldronJ. </plain></SENT>
<SENT sid="451" pm="."><plain>L.AshbyH. </plain></SENT>
<SENT sid="452" pm="."><plain>L.CornesM. </plain></SENT>
<SENT sid="453" pm="."><plain>P.Vitamin D: a negative acute phase reactantJournal of Clinical Pathology201366762062210.1136/jclinpath-2012-2013012-s2.0-8487941199223454726 </plain></SENT>
</text></ref><ref id="B96"><text><SENT sid="454" pm="."><plain>96CantornaM. </plain></SENT>
<SENT sid="455" pm="."><plain>T.MunsickC.BemissC.MahonB. </plain></SENT>
<SENT sid="456" pm="."><plain>D.1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel diseaseJournal of Nutrition200013011264826522-s2.0-003374512511053501 </plain></SENT>
</text></ref><ref id="B97"><text><SENT sid="457" pm="."><plain>97DanielC.RadekeH. </plain></SENT>
<SENT sid="458" pm="."><plain>H.SartoryN. </plain></SENT>
<SENT sid="459" pm="."><plain>A.The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in miceJournal of Pharmacology and Experimental Therapeutics2006319262263110.1124/jpet.106.1075992-s2.0-3375115986116914561 </plain></SENT>
</text></ref><ref id="B98"><text><SENT sid="460" pm="."><plain>98LavernyG.PennaG.VetranoS.Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel diseaseImmunology Letters20101311495810.1016/j.imlet.2010.03.0062-s2.0-7795440364320350569 </plain></SENT>
</text></ref><ref id="B99"><text><SENT sid="461" pm="."><plain>99VerlindenL.LeyssensC.BeullensI.The vitamin D analog TX527 ameliorates disease symptoms in a chemically induced model of inflammatory bowel diseaseThe Journal of Steroid Biochemistry and Molecular Biology2013136110711110.1016/j.jsbmb.2012.09.0172-s2.0-8488112485623000190 </plain></SENT>
</text></ref><ref id="B100"><text><SENT sid="462" pm="."><plain>100OoiJ. </plain></SENT>
<SENT sid="463" pm="."><plain>H.LiY.RogersC. </plain></SENT>
<SENT sid="464" pm="."><plain>J.CantornaM. </plain></SENT>
<SENT sid="465" pm="."><plain>T.Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitiJournal of Nutrition2013143101679168610.3945/jn.113.1807942-s2.0-8488569335923966330 </plain></SENT>
</text></ref><ref id="B101"><text><SENT sid="466" pm="."><plain>101AssaA.VongL.PinnellL. </plain></SENT>
<SENT sid="467" pm="."><plain>J.Vitamin D deficiency predisposes to adherent-invasive Escherichia coli-induced barrier dysfunction and experimental colonic injuryInflammatory Bowel Diseases201521229730610.1097/MIB.000000000000028225590952 </plain></SENT>
</text></ref><ref id="B102"><text><SENT sid="468" pm="."><plain>102TaoQ.WangB.ZhengY.JiangX.PanZ.RenJ.Vitamin D prevents the intestinal fibrosis via induction of vitamin D receptor and inhibition of transforming growth factor-beta1/smad3 pathwayDigestive Diseases and Sciences201410.1007/s10620-014-3398-6 </plain></SENT>
</text></ref><ref id="B103"><text><SENT sid="469" pm="."><plain>103ArdizzoneS.CassinottiA.TrabattoniD.Immunomodulatory effects of 1,25-dihydroxyvitamin D3 on Th1/Th2 cytokines in inflammatory bowel disease: an in vitro studyInternational Journal of Immunopathology and Pharmacology200922163712-s2.0-6264910726119309553 </plain></SENT>
</text></ref><ref id="B104"><text><SENT sid="470" pm="."><plain>104Bendix-StruveM.BartelsL. </plain></SENT>
<SENT sid="471" pm="."><plain>E.AgnholtJ.DigeA.JørgensenS. </plain></SENT>
<SENT sid="472" pm="."><plain>P.DahlerupJ. </plain></SENT>
<SENT sid="473" pm="."><plain>F.Vitamin D3 treatment of Crohns disease patients increases stimulated T cell IL-6 production and proliferationAlimentary Pharmacology &amp; Therapeutics20103211-121364137210.1111/j.1365-2036.2010.04463.x2-s2.0-7844928323621050239 </plain></SENT>
</text></ref><ref id="B105"><text><SENT sid="474" pm="."><plain>105StioM.MartinesiM.BruniS.The Vitamin D analogue TX 527 blocks NF-kappaB activation in peripheral blood mononuclear cells of patients with Crohn's diseaseJournal of Steroid Biochemistry and Molecular Biology20071031516010.1016/j.jsbmb.2006.07.0082-s2.0-3375140050917049230 </plain></SENT>
</text></ref><ref id="B106"><text><SENT sid="475" pm="."><plain>106BartelsL. </plain></SENT>
<SENT sid="476" pm="."><plain>E.BendixM.HvasC. </plain></SENT>
<SENT sid="477" pm="."><plain>L.Oral vitamin D3 supplementation reduces monocyte-derived dendritic cell maturation and cytokine production in Crohn's disease patientsInflammopharmacology20142229510310.1007/s10787-013-0197-124374976 </plain></SENT>
</text></ref><ref id="B107"><text><SENT sid="478" pm="."><plain>107MihellerP.MuzesG.HritzI.Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patientsInflammatory Bowel Diseases200915111656166210.1002/ibd.209472-s2.0-7254908696419408329 </plain></SENT>
</text></ref><ref id="B108"><text><SENT sid="479" pm="."><plain>108JørgensenS. </plain></SENT>
<SENT sid="480" pm="."><plain>P.AgnholtJ.GlerupH.Clinical trial: vitamin D3 treatment in Crohn's disease—a randomized double-blind placebo-controlled studyAlimentary Pharmacology and Therapeutics201032337738310.1111/j.1365-2036.2010.04355.x2-s2.0-7795432486320491740 </plain></SENT>
</text></ref><ref id="B109"><text><SENT sid="481" pm="."><plain>109YangL.WeaverV.SmithJ. </plain></SENT>
<SENT sid="482" pm="."><plain>P.BingamanS.HartmanT. </plain></SENT>
<SENT sid="483" pm="."><plain>J.CantornaM. </plain></SENT>
<SENT sid="484" pm="."><plain>T.Therapeutic effect of vitamin D supplementation in a pilot study of Crohn's patientsClinical and Translational Gastroenterology20134, article e3310.1038/ctg.2013.12-s2.0-84885743052 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="485" pm="."><plain>Potential involvement of vitamin D in the pathogenesis of inflammatory bowel disease and immunologic effects of vitamin-D-related therapeutic approaches. </plain></SENT>
<SENT sid="486" pm="."><plain>Scenario A: reduced UV exposure as risk factor for CD and for hospitalizations and surgery [86]; Scenario B: NOD2 gene transcription is stimulated by 1,25(OH)2D3/VDR and signaling through NOD2 induces expression of DEFB2/HBD2 which stands for beta-defensin 2 and cathelicidin [20]; Scenarios C and D: variants or loss of function of VDR may lead to changes of the microbiota and reduce host defense by reducing production of cathelicidin, lysozyme, and ATG16L1 protein (autophagy) [21, 22]; Scenario E: experimental studies with vitamin D or its analogues showing inhibitory effects on PBMC, LPMC, dendritic cells, and fibroblasts in terms of cytokine production and differentiation (Table 3). </plain></SENT>
<SENT sid="487" pm="."><plain>VDR: vitamin D receptor; NOD: nucleotide-binding oligomerization domain. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2015-470805.001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="488" pm="."><plain>Genetic polymorphisms and IBD (chronological order). </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="489" pm="."><plain>Author </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="490" pm="."><plain>Year </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="491" pm="."><plain>Population </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="492" pm="."><plain>Investigated gene polymorphisms </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="493" pm="."><plain>Main findings </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="494" pm="."><plain>Single- or multicenter studies </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="495" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="496" pm="."><plain>Simmons et al. [23] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="497" pm="."><plain>2000 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="498" pm="."><plain>England 158 UC, 245 CD,164 CRADC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="499" pm="."><plain>VDR: TaqI, ApaI, FokI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="500" pm="."><plain>TaqI polymorphism (“tt” genotype) more frequent in CD compared to UC or controls </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="501" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="502" pm="."><plain>Martin et al. [24] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="503" pm="."><plain>2002 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="504" pm="."><plain>Germany, 95 CD, 93 UC, 119 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="505" pm="."><plain>VDR: TaqI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="506" pm="."><plain>TaqI (“tt” genotype) significantly more frequent in fistulizing and stenosing CD </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="507" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="508" pm="."><plain>Dresner-Pollak et al. [36] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="509" pm="."><plain>2004 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="510" pm="."><plain>Israel, 228 CD (129 Ashkenazi and 99 non-Ashkenazi), 151 UC (72 Ashkenazi, 79 non-Ashkenazi), 495 HC (352 non-Ashkenazi and 143 Ashkenazi) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="511" pm="."><plain>VDR: BsmI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="512" pm="."><plain>BB genotype more frequent in Ashkenazi UC compared to Ashkenazi HC </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="513" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="514" pm="."><plain>Noble et al. [34] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="515" pm="."><plain>2008 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="516" pm="."><plain>United Kingdom, 286 CD, 154 UC, 240 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="517" pm="."><plain>VDR: TaqI, ApaI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="518" pm="."><plain>Overall no differences between CD, UC, and HC for TaqI and ApaI. </plain></SENT>
<SENT sid="519" pm="."><plain>TaqI variants more frequent in male IBD patients compared to (male) HC </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="520" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="521" pm="."><plain>Naderi et al. [37] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="522" pm="."><plain>2008 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="523" pm="."><plain>Iran, 150 UC, 80 CD, 150 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="524" pm="."><plain>VDR: ApaI, TaqI, BsmI, FokI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="525" pm="."><plain>FokI polymorphism significantly higher in UC and CD. </plain></SENT>
<SENT sid="526" pm="."><plain>Frequency of polymorphic “f” allele and f/f genotype higher in UC and CD comparing with HC </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="527" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="528" pm="."><plain>Pluskiewicz et al. [30] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="529" pm="."><plain>2009 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="530" pm="."><plain>Poland, 47 UC, 47 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="531" pm="."><plain>VDR: TaqI, BsmI, ApaI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="532" pm="."><plain>No differences between UC and HC </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="533" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="534" pm="."><plain>Hughes et al. [29] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="535" pm="."><plain>2011 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="536" pm="."><plain>Ireland, 660 IBD, 699 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="537" pm="."><plain>VDR: ApaI, TaqI, BsmI, FokI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="538" pm="."><plain>Borderline significance for heterozygous carriage of the FokI allele </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="539" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="540" pm="."><plain>Pei et al. [31] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="541" pm="."><plain>2011 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="542" pm="."><plain>China, 218 UC, 251 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="543" pm="."><plain>VDR: ApaI, TaqI, BsmI, FokI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="544" pm="."><plain>Only Bb genotype of the BsmI variant associated with UC; frequency of the BsmI polymorphic allele (B) increased in UC </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="545" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="546" pm="."><plain>Eloranta et al. [42] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="547" pm="."><plain>2011 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="548" pm="."><plain>Switzerland, 404 CD, 232 UC, 248 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="549" pm="."><plain>DBP: rs 7041, rs 4588 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="550" pm="."><plain>Significantly reduced frequency of the 420 variant Lys in IBD compared to controls </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="551" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="552" pm="."><plain>Bentley et al. [35] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="553" pm="."><plain>2011 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="554" pm="."><plain>New Zealand, 449 CD, 448 UC, 482 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="555" pm="."><plain>VDR: FokI, TaqI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="556" pm="."><plain>No overall differences, only a higher minor allele frequency for TaqI, in male CD and UC compared to HC </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="557" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="558" pm="."><plain>Luo et al. [33]* </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="559" pm="."><plain>2013 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="560" pm="."><plain>China, 19 CD, 122 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="561" pm="."><plain>VDR: ApaI, TaqI, BsmI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="562" pm="."><plain>No significant differences in the frequencies of TaqI, BsmI, and ApaI polymorphisms </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="563" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="564" pm="."><plain>Xia et al. [32] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="565" pm="."><plain>2014 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="566" pm="."><plain>China 382 UC, 489 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="567" pm="."><plain>VDR: ApaI, TaqI, BsmI, FokI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="568" pm="."><plain>No difference between UC and HC. </plain></SENT>
<SENT sid="569" pm="."><plain>The mutant allele C and genotype TC + CC of FokI were significantly increased in patients with mild and moderate UC compared to severe UC. </plain></SENT>
<SENT sid="570" pm="."><plain>The frequency of AAC haplotype was statistically lower in UC than HC (AAC haplotype formed by the VDR BsmI, ApaI, and TaqI gene might engender a reduced risk of UC attack) </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="571" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="572" pm="."><plain>Meta-analyses </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="573" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="574" pm="."><plain>Xue et al. [38] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="575" pm="."><plain>2013 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="576" pm="."><plain>ApaI: 1024 CD, 974 UC, 1551 HCFokI: 1187 CD, 1221 UC, 1746 HCBsmI: 721 CD, 813 UC, 1642 HCTaqI: 1568 CD, 1515 UC, 2152 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="577" pm="."><plain>VDR: ApaI, TaqI, BsmI, FokI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="578" pm="."><plain>FokI “ff” genotype associated with a significant risk for UC in Asians; TaqI “tt” genotype associated with an increased risk for CD in Europeans and with an increased risk for CD and UC in Asian males. </plain></SENT>
<SENT sid="579" pm="."><plain>ApaI “a” allele confers protection from CD </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="580" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="581" pm="."><plain>Wang et al. [39] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="582" pm="."><plain>2014 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="583" pm="."><plain>ApaI: 940 CD, 962 UC, 1468 HCFokI: 1098 CD, 1217 UC, 1676 HCBsmI: 713 CD, 799 UC, 1616 HCTaqI: 1553 CD, 1500 UC, 2145 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="584" pm="."><plain>VDR: ApaI, TaqI, BsmI, FokI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="585" pm="."><plain>ApaI, BsmI, and FokI are not significantly associated with IBD. </plain></SENT>
<SENT sid="586" pm="."><plain>Significant association between TaqI polymorphism and IBD risk. In subgroups, ApaI increases the overall CD risk and BsmI increases this CD risk only in East Asians, whereas TaqI reduces the risk for UC especially in Caucasians </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>CD: Crohn's disease; UC: ulcerative colitis; CRADC: cadaveric renal allograft donor controls; PCR: polymerase chain reaction; IBD: inflammatory bowel disease; HC: healthy controls; DBP: vitamin-D-binding protein; VDR: vitamin D receptor.</p></fn><fn><p>
<sup>*</sup>Article in Chinese.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p><text><SENT sid="587" pm="."><plain>Vitamin D versus disease activity and outcome in IBD (chronological order). </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="588" pm="."><plain>Author </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="589" pm="."><plain>Year </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="590" pm="."><plain>Population </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="591" pm="."><plain>Methodology </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="592" pm="."><plain>Main findings </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="593" pm="."><plain>Harries et al. [50] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="594" pm="."><plain>1985 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="595" pm="."><plain>U.S.A40 CD20 UC9 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="596" pm="."><plain>Single-center cohort; CD divided into 2 groups (undernourished and well nourished); 2 control groups: 20 well-nourished UC and 9 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="597" pm="."><plain>25(OH)D3 significantly lower in CD with active disease versus inactive disease (P &lt; 0.05) </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="598" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="599" pm="."><plain>Tajika et al. [46] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="600" pm="."><plain>2004 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="601" pm="."><plain>Japan33 CD, 11 UC, 15 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="602" pm="."><plain>Single-center cohort; 25(OH)D3 and disease activity assessed by CDAI and IOIBD score </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="603" pm="."><plain>Serum 25(OH)D3 significantly related to disease duration (r = 0.46, P = 0.003), CDAI (r = 0.44, P = 0.005), IOIBD score (r = 0.30, P &lt; 0.05), serum ferritin (r = 0.34, P = 0.03), CRP (r = 0.34, P = 0.03) </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="604" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="605" pm="."><plain>Joseph et al. [52] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="606" pm="."><plain>2009 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="607" pm="."><plain>India34 CD, 34 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="608" pm="."><plain>Single-center cohort; disease activity evaluated by HBI in CD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="609" pm="."><plain>Serum 25(OH)D3 in CD significantly lower versus controls (P &lt; 0.05). </plain></SENT>
<SENT sid="610" pm="."><plain>Disease activity correlated negatively with 25(OH)D3 level (P &lt; 0.004). </plain></SENT>
<SENT sid="611" pm="."><plain>25(OH)D3 levels were comparable to controls in mild CD but were significantly lower in moderate and severe CD </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="612" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="613" pm="."><plain>Nakajima et al. [68] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="614" pm="."><plain>2011 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="615" pm="."><plain>Japan47 CD, 40 UC, 41 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="616" pm="."><plain>Single-center cohort; disease activity measured using CAI/CDAI scores </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="617" pm="."><plain>No decrease 1,25(OH)2D3 in CD with high CDAI No significant correlation between serum 1,25(OH)2D3 levels and CAI or CDAI in UC or CD </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="618" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="619" pm="."><plain>Ulitsky et al. [59] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="620" pm="."><plain>2011 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="621" pm="."><plain>U.S.A.504 IBD (403 CD, 101 UC) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="622" pm="."><plain>Single-center cohort; retrospective observational study HRQOL measured with SIBDQ, disease activity measured using HBI/UCDI scores </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="623" pm="."><plain>25(OH)D3 deficiency significantly associated with lower SIBDQ (P = 0.002) and higher mean HBI/UCDI (P = 0.002) in IBD versus vit D sufficient patients. </plain></SENT>
<SENT sid="624" pm="."><plain>Analyzed separately, vit D deficiency associated with lower HRQOL scores only in CD (P = 0.04), not in UC </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="625" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="626" pm="."><plain>El-Matary et al. [54] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="627" pm="."><plain>2011 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="628" pm="."><plain>Canada60 IBD (39 CD, 21 UC) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="629" pm="."><plain>Cross-sectional pediatric study. </plain></SENT>
<SENT sid="630" pm="."><plain>Disease activity measured by PCDAI e PUCAI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="631" pm="."><plain>No correlation between PCDAI and serum 25(OH)D3. </plain></SENT>
<SENT sid="632" pm="."><plain>Marginal evidence against the null hypothesis (P = 0.05) between serum 25(OH)D3 and PUCAI, but without statistical significance </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="633" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="634" pm="."><plain>Hassan et al. [60] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="635" pm="."><plain>2013 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="636" pm="."><plain>Iran60 IBD (34 UC, 26 CD) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="637" pm="."><plain>Cross-sectional study. </plain></SENT>
<SENT sid="638" pm="."><plain>Disease activity measured by CDAI and Truelove index </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="639" pm="."><plain>Serum vit D lower in active versus inactive disease (non significantly). </plain></SENT>
<SENT sid="640" pm="."><plain>VitD deficiency was not associated with IBD activity (also considering CD and UC separately), however was associated with a history of IBD related intestinal surgery </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="641" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="642" pm="."><plain>Ananthakrishnan et al. [81] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="643" pm="."><plain>2013 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="644" pm="."><plain>U.S.A.3,217 IBD (55% CD, 45% UC) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="645" pm="."><plain>Multicenter cohort; 25(OH)D3: Normal (&gt;30 ng/mL), Insufficient (20–29.9 ng/mL) or Deficient (&lt;20 ng/mL) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="646" pm="."><plain>IBD-related surgery: CD: 10% patients never vitamin D deficient versus 13% vitamin D insufficient versus 17% vitamin D deficient. </plain></SENT>
<SENT sid="647" pm="."><plain>UC: vitamin D deficiency associated with elevated risk of surgery and hospitalization with effect similar to CD; no statistical significance in patients vitamin D insufficient.Normalization of 25(OH)D3 associated with reduction in the risk of related surgery but not in UC </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="648" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="649" pm="."><plain>Zator et al. [92] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="650" pm="."><plain>2014 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="651" pm="."><plain>U.S.A.101 IBD (74 CD, 27 UC) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="652" pm="."><plain>Retrospective single-center cohort; patients on anti-TNF therapy evaluated for loss of response; 25(OH)D3 insufficiency: &lt;30 ng/mL </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="653" pm="."><plain>Patients with insufficient vitamin D demonstrated earlier cessation of anti-TNF-α therapy (P = 0.04). </plain></SENT>
<SENT sid="654" pm="."><plain>This effect was significant in patients who stopped treatment for loss of response, stronger for CD than UC (P = NS) </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="655" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="656" pm="."><plain>Ananthakrishnan et al. [91] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="657" pm="."><plain>2014 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="658" pm="."><plain>U.S.A.3188 IBD patients (45% UC, 55% CD) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="659" pm="."><plain>Retrospective multi-center analysis of 25(OH)D3 in 35 patients who developed CDI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="660" pm="."><plain>25(OH)D3 level was significantly lower in IBD who developed CDI compared to non-CDI-IBD (P = 0.002). </plain></SENT>
<SENT sid="661" pm="."><plain>Levels below 20 ng/mL were associated with a two-fold increase in risk of CDI.25(OH)D3 level was an independent predictor of CDI </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="662" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="663" pm="."><plain>Ham et al. [93] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="664" pm="."><plain>2014 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="665" pm="."><plain>U.S.A.37 CD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="666" pm="."><plain>Prospectively collected samples for 25(OH)D3 analysis; assessment of HBI and CRPPBMC tested for VDR, Cyp </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="667" pm="."><plain>25(OH)D3 levels lower in patients with active disease versus inactive disease, 25(OH)D3 correlated with HBI (not with CRP)PBMC: mean gene expression of VDR and CypB1 higher in active disease </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="668" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="669" pm="."><plain>Garg et al. [90] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="670" pm="."><plain>2013 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="671" pm="."><plain>Australia40 CD31 UC23 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="672" pm="."><plain>Assessment of 25(OH)D3, fecal calprotectin and CRP </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="673" pm="."><plain>Inverse correlation between serum 25(OH)D3 and fecal calprotectin in CD and UC patients, but not with CRP </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="674" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="675" pm="."><plain>Hlavaty et al. [82] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="676" pm="."><plain>2014 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="677" pm="."><plain>Slovakia141 CD49 UC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="678" pm="."><plain>SIBDQ assessment in vitamin D sufficient or -deficient patients and in vitamin supplement (800 IU/day for 3 months) patients </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="679" pm="."><plain>SIBDQ was significantly better in vitamin D-sufficient patients;vitamin D supplements did not influence vitamin D status or sIBDQ </plain></SENT>
</text></td></tr><tr><td align="center" colspan="5" rowspan="1"><text><SENT sid="680" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="681" pm="."><plain>Govani et al. [88] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="682" pm="."><plain>2015 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="683" pm="."><plain>U.S.A.67,751 CD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="684" pm="."><plain>Retrospective, national, analysis of UV exposure and inpatient surgery risk </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="685" pm="."><plain>UV exposure protective for inpatients surgery </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CD: Crohn's disease; UC: ulcerative colitis; HC: healthy controls; IBS: irritable bowel syndrome; IBD: inflammatory bowel disease; CDAI: Crohn's Disease Activity Index; IOIBD: international organization for the study of inflammatory bowel disease score; CAI: Lichtiger's clinical activity index; 25(OH)D<sub>3</sub>: 25-Hydroxycholecalciferol; 1,25(OH)<sub>2</sub>D<sub>3</sub>: 1,25dihydroxycholecalciferol; SIBDQ: Short IBD Questionnaire; HBI: Harvey-Bradshaw index; UCDI: Ulcerative colitis disease activity index; HRQOL: health-related quality of life; PCDAI: pediatric Crohn's disease activity index; PUCAI: pediatric ulcerative colitis activity index; CDI: Clostridium difficile infection; CRP: C-reactive protein; UV: ultraviolet; TNF: tumor necrosis factor; PBMC: peripheral blood mononuclear cells; Cyp: Cyp27b1 gene; VDR: vitamin D receptor.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p><text><SENT sid="686" pm="."><plain>Therapeutic studies in experimental and human IBD (chronological order). </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="687" pm="."><plain>Author </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="688" pm="."><plain>Year </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="689" pm="."><plain>Species/cells </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="690" pm="."><plain>Investigational agent </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="691" pm="."><plain>Methodology </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="692" pm="."><plain>Main findings </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="693" pm="."><plain>Animal and in vitro studies </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="694" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="695" pm="."><plain>Cantorna et al. [96] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="696" pm="."><plain>2000 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="697" pm="."><plain>IL-10 KO mice </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="698" pm="."><plain>1,25(OH)2D3 p.o. </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="699" pm="."><plain>Exp. </plain></SENT>
<SENT sid="700" pm="."><plain>1. </plain></SENT>
<SENT sid="701" pm="."><plain>Vit. </plain></SENT>
<SENT sid="702" pm="."><plain>D-deficient IL-10 KO mice versus vit. </plain></SENT>
<SENT sid="703" pm="."><plain>D-sufficient mice (treated with cholecalciferol);Exp. </plain></SENT>
<SENT sid="704" pm="."><plain>2. </plain></SENT>
<SENT sid="705" pm="."><plain>Vit. </plain></SENT>
<SENT sid="706" pm="."><plain>D-deficient IL10 KO mice versus 1,25(OH)2D3- treated;Exp. </plain></SENT>
<SENT sid="707" pm="."><plain>3. </plain></SENT>
<SENT sid="708" pm="."><plain>Vit. </plain></SENT>
<SENT sid="709" pm="."><plain>D treatment after onset of GI symptoms </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="710" pm="."><plain>Vitamin D sufficiency prevents enterocolitis in IL-10 KO mice up to 13 weeks; 1,25(OH)2D3 treatment ameliorates inflammation </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="711" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="712" pm="."><plain>Daniel et al. [97] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="713" pm="."><plain>2006 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="714" pm="."><plain>BALB/c mice </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="715" pm="."><plain>TNBS colitis; 22-ene-25-oxa-vitamin D (ZK156979) i.p.(vitamin D analogue) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="716" pm="."><plain>Treatment with ZK156979 versus 1,25(OH)2D3 before or after induction of colitis with TNBS; investigation of tissue MPO, TNF-α, IFN-γ, T-bet, IL-10, and IL-4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="717" pm="."><plain>ZK156979 versus 1,25(OH)2D3 prevents or ameliorates TNBS colitis decreasing pro-inflammatory and increasing anti-inflammatory cytokines </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="718" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="719" pm="."><plain>Laverny et al. [98] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="720" pm="."><plain>2010 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="721" pm="."><plain>C57BL/6 mice </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="722" pm="."><plain>DSS-colitis, 1α,25(OH)2-16-ene-20-cyclopropyl-vitamin D3 (BXL-62) (=VDR agonist) intrarectally </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="723" pm="."><plain>Daily administration of BXL-62 versus 1,25(OH)2D3;Macro- and microscopic scoring; mucosal concentrations of TNF-α, IL-12/23p40, IL-6, and IFN-γ and assessment of mRNA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="724" pm="."><plain>Higher potency of BXL-62 versus 1,25(OH)2D3 in reducing tissue inflammation </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="725" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="726" pm="."><plain>Verlinden et al. [99] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="727" pm="."><plain>2013 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="728" pm="."><plain>C57BL/6 mice </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="729" pm="."><plain>DSS- colitis 1α,25(OH)2-19-nor-14,20-bisepi-23-yne-vitamin D3 (TX527) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="730" pm="."><plain>Histological examination; measurement of transcript levels of cytokines (IL-1, IL-6, IFN-γ, and TNF-α) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="731" pm="."><plain>TX527 reduced “clinical” disease scores and attenuated histological scores, downregulation of transcript levels of inflammatory cytokines </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="732" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="733" pm="."><plain>Ooi et al. [100] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="734" pm="."><plain>2013 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="735" pm="."><plain>C57BL/6 miceCyp KO VDR KO </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="736" pm="."><plain>1,25(OH)2D3 p.o. </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="737" pm="."><plain>DSS colitis; characterization of gut microbiota, andgut macrophages; E-cadherin expression </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="738" pm="."><plain>Lower expression of E cadherin and tolerogenic macrophagesLess beneficial microbiota in KO miceVitamin D treatment ameliorates colitis and reduces Helicobacteraceae </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="739" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="740" pm="."><plain>Wu et al. [21] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="741" pm="."><plain>2014 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="742" pm="."><plain>Conditional VDR KO and IL-10 KO miceDSS-colitiscells: MEF, SKCO15, HCT116human tissue </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="743" pm="."><plain>DSS colitisBUT feeding in IL-10 KO </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="744" pm="."><plain>VDR KO: colitis evaluation, pyrosequencing for microbiota, Paneth cells, lysozyme production, autophagyMEF (VDR−/− VDR+/− VDR+/+) and VDR knockdown in SKCO15 with evaluation of ATG16L1 and LC3B proteinsIL-10 KO: VDR and ATG16L1 expression with or w/o BUT feeding Human tissue (UC, inflamed versus normal) VDR, ATG16L1, Bacteroides concentration (FISH)HCT116 and HIEC: VDR expression with and w/o incubation with BUT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="745" pm="."><plain>Conditional VDR KO mice: worse colitis, increased E. coli and Bacteroides (B. fragilis), and decreased BUT-producing bacteria; less and abnormal Paneth cells and reduced lysozyme and ATG16L1 protein; in SKCO15 and MEF reduced expression of ATG16L1 and LC3B proteinsIn UC: reduced expression of VDR and ATG16L1, increase of Bacteroides;BUT increases VDR expression in HIEC and HCT116 </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="746" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="747" pm="."><plain>Tao et al. [102] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="748" pm="."><plain>2014 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="749" pm="."><plain>C57BL/6 mice </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="750" pm="."><plain>TNBS-colitisVitamin D sufficient or deficient diet </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="751" pm="."><plain>At week 14, assessment of ECM and total collagen production, together with determination in isolated colonic SEMF, of expression of VDR, α-SMA, and Collagen I in normal SEMF </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="752" pm="."><plain>Histological scoring, ECM, and collagen production in the colon reduced in vitamin D supplemented mice; in SEMF decreased levels of TGF-β1, Smad-3, p-Smad3, and Collagen I and induced VDR expression and decreased TGF-β1-induced α-SMA and Collagen I expression </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="753" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="754" pm="."><plain>Assa et al. [101] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="755" pm="."><plain>2015 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="756" pm="."><plain>Caco cellsC57BL/6 mice </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="757" pm="."><plain>DSS- colitisVitamin D sufficient or deficient diet1,25(OH)2D3 for Caco </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="758" pm="."><plain>Caco cells incubated with or w/o 1,25(OH)2D3 challenged with AIECC57BL/6 mice on normal or low 1,25(OH)2D3 diet infected with AIEC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="759" pm="."><plain>1,25(OH)2D3 protects Caco cells against AIEC induced loss of TER and TJ protein redistribution1,25(OH)2D3 reduces DSS colitis and AIEC invasionlow vitamin D diet and DSS colitis increased Bacteroides </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="760" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="761" pm="."><plain>In vivo and ex vivo studies in IBD patients </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="762" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="763" pm="."><plain>Stio et al. [105] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="764" pm="."><plain>2007 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="765" pm="."><plain>4 CD and 4 HC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="766" pm="."><plain>TX 527 [19-nor-14,20-bisepi-23-yne-1,25(OH)2D3], Vitamin D analogue </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="767" pm="."><plain>Single-center, ex vivo study;experimental study on PBMC of CD patients </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="768" pm="."><plain>TX 527 inhibits TNF-α mediated effects on PBMC and the activation of NF-κB; its action is mediated by VDR </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="769" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="770" pm="."><plain>Miheller et al. [107] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="771" pm="."><plain>2009 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="772" pm="."><plain>37 CD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="773" pm="."><plain>Group A treated with aVD versus group B treated with pVD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="774" pm="."><plain>Single-center study; evaluation of bone parameters and CDAI, CRP, and SIBDQ after 6, 12, 52 weeks </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="775" pm="."><plain>In aVD, after 6 weeks (but not at 52 weeks) a significant reduction of CDAI, IBDQ, and CRP together with a significant change of bone parameters </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="776" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="777" pm="."><plain>Ardizzone et al. [103] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="778" pm="."><plain>2009 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="779" pm="."><plain>9 UC, 8 CD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="780" pm="."><plain>1,25(OH)2D3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="781" pm="."><plain>Single-center ex vivo study; PBMC with or without calcitriol; determination of TNF-α, IFN-γ, IL-2, and IL-10 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="782" pm="."><plain>In UC PBMC 1,25(OH)2D3 reduced IFN-γ and enhanced IL-10 productionIn CD PBMC 1,25(OH)2D3 reduced TNF-α production </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="783" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="784" pm="."><plain>Jørgensen et al. [108] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="785" pm="."><plain>2010 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="786" pm="."><plain>94 CD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="787" pm="."><plain>Vitamin D3 versus placebo </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="788" pm="."><plain>Multi-center randomized double-blind placebo-controlled study;1200 IU vit D3/day or placebo; estimation of clinical relapse rate </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="789" pm="."><plain>Vit. </plain></SENT>
<SENT sid="790" pm="."><plain>D3 significantly increasedserum vit. </plain></SENT>
<SENT sid="791" pm="."><plain>D levels, but the decrease of relapse was not significant (13% versus 29%, P = 0.06) </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="792" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="793" pm="."><plain>Bendix-Struve et al. [104] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="794" pm="."><plain>2010 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="795" pm="."><plain>108 CD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="796" pm="."><plain>Vitamin D3 versus placebo </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="797" pm="."><plain>Randomized, placebo-controlled, clinical trial After 0, 36, and 52 weeks, PBMC tested in 10 patients treated with Vitamin D3 (1200 IU/day) and in 10 patients treated with placebo for cytokine production and proliferation </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="798" pm="."><plain>Vit. </plain></SENT>
<SENT sid="799" pm="."><plain>D3 treatment of CD patients increased the IL-6 levels and enhance the CD4+ T-cell proliferation </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="800" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="801" pm="."><plain>Laverny et al. [98] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="802" pm="."><plain>2010 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="803" pm="."><plain>22 CD, 21 UC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="804" pm="."><plain>1α,25(OH)2-16-ene-20-cyclopropyl-vitamin D3 (BXL-62) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="805" pm="."><plain>Ex vivo preparations of PBMC (+LPS) and (CD2/CD28 activated)-LPMCs incubated with or without BXL-62.Determination of mRNA and protein concentrations of TNF-α, IL-12/23p40, IL-6, and IFN-γ </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="806" pm="."><plain>Higher anti-inflammatory potency compared to 1,25(OH)2D3 demonstrated by the significantly more potent inhibition in PBMC and in LPMCs of the proinflammatory cytokines TNF-α, IL-12/23p40, IL-6, and IFN-γ </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="807" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="808" pm="."><plain>Yang et al. [109] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="809" pm="."><plain>2013 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="810" pm="."><plain>18 CD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="811" pm="."><plain>Vitamin D3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="812" pm="."><plain>Open-label prospective clinical trial over 24 weeks, multi-center study; vitamin D3 at 1000 IU/day; dose increase every two week of 1000 IU/day up to 5000 IU/day to achieve serum 25(OH)D3 &gt;40 ng/mL </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="813" pm="."><plain>Vit. </plain></SENT>
<SENT sid="814" pm="."><plain>D3 supplementation significantly raised serum 25(OH)D3, reduced CDAI scores, and improved IBDQ scores </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="815" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="816" pm="."><plain>Bartels et al. [106] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="817" pm="."><plain>2014 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="818" pm="."><plain>10 CD </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="819" pm="."><plain>Vitamin D3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="820" pm="."><plain>Single-center study, oral vitamin D supplementation (or placebo) and assessment of maturation marker expression and cytokine production of monocyte-derived dendritic cells </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="821" pm="."><plain>Dendritic cells from vitamin supplemented CD patients exhibited reduced expression of CD80 and reduced production of the cytokines IL-10, IL-1β, and IL-6 </plain></SENT>
</text></td></tr><tr><td align="center" colspan="6" rowspan="1"><text><SENT sid="822" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="823" pm="."><plain>Ham et al. [93] </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="824" pm="."><plain>2014 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="825" pm="."><plain>PBMC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="826" pm="."><plain>Incubation of CD4+ with vit D 50 nM </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="827" pm="."><plain>Determination of CD25+ and CD39+ cells </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="828" pm="."><plain>3-fold increase of CD25+ cells, CD39+ unchanged </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>CD: Crohn's disease; UC: ulcerative colitis; HC: healthy controls; vit: vitamin; p.o.: per os; GI: gastrointestinal; KO: knock-out; TNBS: 2,4,6-trinitrobenzene sulfonic acid; i.p.: intraperitoneal; DSS: dextran sodium sulfate; 25(OH)D: 25-hydroxycholecalciferol; 1,25(OH)<sub>2</sub>D<sub>3</sub>: 1,25-dihydroxycholecalciferol; vitamin D3 (vit D3): cholecalciferol; VDR: vitamin D receptor; MEF: mouse embryonic fibroblasts; AIEC: adherent-invasive <italic>Escherichia coli</italic>; TER: transepithelial electrical resistance; TJ: tight-junction; aVD: active vitamin D (1,25(OH)<sub>2</sub>D<sub>3</sub>); pVD: plain vitamin D (25(OH)vitamin D); CDAI: Crohn's disease activity index; CRP: C-reactive protein; SIBDQ: Short IBD questionnaire; PBMC: peripheral blood mononuclear cells; LPS, lipopolysaccharide; LPMCs: lamina propria mononuclear cells; IBDQ: IBD questionnaire; IL: interleukin; Cyp: Cyp27b1 gene; IFN: interferon; TNF: tumor necrosis factor; BUT butyrate; SEMF: subepithelial myofibroblasts; ECM: extracellular matrix; <italic>α</italic>-SMA: alpha smooth muscle actin; FISH: fluorescent in situ hybridization; HIEC: human intestinal epithelial cells; ATG16L1: autophagy related 16-like 1 (<italic>S. cerevisiae</italic>); LC3B: autophagy-related protein LC3B; SKCO15: human colorectal adenocarcinoma cells; HCT116: human colon cancer cell.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
